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ABL v-abl Abelson murine leukemia viral oncogene homolog 1
AKT v-akt murine thymoma viral oncogene homolog
APC adenomatous polyposis coli
BAX BCL2-associated X protein
BCR breakpoint cluster region
BRAF v-raf murine sarcoma viral oncogene homolog
BRCA1, 2 breast and ovarian cancer gene 1, 2
CD44 CD44 molecule (Indian blood group)
CDX2 caudal type homeobox transcription factor 2
CGH comparative genomic hybridization
CIN chromosomal instability
CRC colorectal carcinoma
CT comparative threshold cycle
CTNNB1 -catenin
DAB 3,3’ diaminobenzidine (chromogen)
EC endometrial carcinoma
ERG v-ets erythroblastosis virus E26 oncogene homolog
ETV1 ets variant gene 1
FAP familial adenomatous polyposis coli
GSK3 glycogen synthase kinase 3
HNPCC hereditary nonpolyposis colorectal cancer
InSiGHT International Society for Gastrointestinal Hereditary Tumors
KRAS Kirsten rat sarcoma viral oncogene homolog
LINE-1 long interspersed nuclear element 1
LOH loss of heterozygosity
MALDI-TOF  matrix-assisted laser desorption/ionization time-of-flight
MLPA multiplex ligation-dependent probe amplification
MLH1, 3 human mutL homolog 1, 3
MMR mismatch repair
MSH2, 3, 6 human mutS homolog 2, 3, 6
MSI microsatellite instability
MS-MLPA methylation specific MLPA
MSS microsatellite stable
MYC v-myc avian myelocytomatosis viral oncogene homolog
MYH mutY homolog (E. coli)
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Nf1 neurofibromatosis type 1
PDK1, 2 pyruvate dehydrogenase kinase, isoenzyme 1, 2
PI3K phosphatidylinositol 3-kinase
PIK3CA phosphatidylinositol 3-kinase catalytic subunit alpha (p110 )
PIP2, 3 phosphatidylinositol biphosphate, triphosphate
PMS1, 2 human postmeiotic segregation increased homolog 1, 2
PTEN phosphatase and tensin homolog
RAS rat sarcoma viral oncogene homolog
Rb1 retinoblastoma 1
SAP shrimp alkaline phosphatase
SNP single nucleotide polymorphism
SNuPE single nucleotide primer extension
TACSTD1 tumor-associated calcium signal transducer 1
TCF-4 transcription factor 4
TGF RII transforming growth factor receptor II
TP53 tumor protein 53
TMPRSS2 transmembrane protease, serine 2
Wnt wingless-type
8
LIST OF ORIGINAL PUBLICATIONS
This thesis is based on the following publications:
I Abdel-Rahman WM, Ollikainen M, Kariola R, Järvinen HJ, Mecklin J-
P,  Nyström-Lahti  M,  Knuutila  S,  Peltomäki  P.  Comprehensive
characterization of HNPCC-related colorectal cancers reveals striking
molecular features in families with no germline mismatch repair gene
mutations. Oncogene 24:1542-1551, 2005
II Ollikainen M, Abdel-Rahman WM, Moisio A-L, Lindroos A, Kariola
R, Järvelä I, Pöyhönen M, Bützow R, Peltomäki P. Molecular analysis
of familial endometrial carcinoma: A manifestation of Hereditary
nonpolyposis  colorectal  cancer  or  a  separate  syndrome? Journal of
Clinical Oncology 23:4609-16, 2005
III Ollikainen M, Hannelius U, Lindgren CM, Abdel-Rahman WM, Kere
J, Peltomäki P. Mechanisms of inactivation of MLH1 in hereditary
nonpolyposis colorectal carcinoma: a novel approach. Oncogene 2007
Jan 29; [Epub ahead of print]
IV Ollikainen  M*,  Gylling  A*,  Puputti  M,  Nupponen  NN,  Abdel-
Rahman WM, Bützow R, Peltomäki P. Patterns of PIK3CA alterations
in familial colorectal and endometrial carcinoma. Submitted
* Equal contribution
The publications are referred to in the text by their roman numerals.
9
ABSTRACT
Colorectal  and  endometrial  cancers  (CRC  and  EC)  are  among  the  three  most
common cancers in Finland, and in other industrial countries, and thus comprise
major public health problems. Approximately 25-30% of all colorectal cancers are
due to some kind of genetic predisposition. Hereditary nonpolyposis colorectal
cancer (HNPCC) is the most common known hereditary cause of CRC. HNPCC is
inherited in a dominant manner with predisposing germline mutations in one of
the known mismatch repair (MMR) genes: MLH1, MSH2, MSH6, and PMS2.
Defective MMR leads to an accumulation of mutations especially in repeat tracts
such as microsatellites leading to unstable microsatellites, which is the hallmark
of HNPCC tumors (and other tumors with deficient MMR). HNPCC is clinically a
very heterogeneous disease, which means that the same predisposing mutation
may lead to different phenotypes, even within a family. The age at onset varies
and the target tissue may vary. HNPCC is actually a cancer syndrome in which
predisposed individuals also have an increased risk for developing cancers other
than CRC. The lifetime risk for CRC is 75-80%, the risk to develop EC is 50%, and
risk  for  tumors  of  the  stomach,  small  intestine,  liver  and  biliary  tract,  pancreas,
ovary, ureter and renal pelvis, and brain is below 15%. To help diagnose this
heterogeneous disease, diagnostic criteria were developed. Families that fulfill the
diagnostic criteria but fail to show any predisposing mutation in MMR genes,
however,  exist.  Studying  such  families  is  likely  to  result  in  the  identification  of
new genes  participating in  MMR or  in  new pathways that  may turn out  to  play
important roles in tumorigenesis and inherited cancer susceptibility.
Our aim was to evaluate the genetic background of familial/hereditary CRC and
EC in MMR proficient and deficient tumors. First,  we performed comprehensive
molecular  and  DNA  copy  number  analyses  of  CRCs  fulfilling  the  diagnostic
criteria for HNPCC.  We studied the role of five pathways (MMR, Wnt, p53, CIN,
and  PI3K/AKT)  and  divided  the  tumors  into  two  groups,  one  with  MMR  gene
germline mutations and the other without. We then compared the observed
characteristics between these two groups. We deduced that MMR gene germline
mutation negative tumors include two different types of CRCs. The majority were
characterized with paucity of common molecular and chromosomal alterations
with stable microsatellites and chromosomes, inactive Wnt pathway, and
infrequent TP53 mutations. The minority showed classical molecular features
representative of tumors with gross chromosomal changes and stable
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microsatellites. The majority of MMR mutation negative HNPCC families seem to
be  due  to  novel  predisposing  genes  and  pathways  that  differ  from  both  those
involved in the development to classical HNPCC tumors and sporadic colorectal
tumors.
Second, we investigated the genetic background of familial ECs. We analyzed the
role  of  MMR  genes  in  families  with  clustered  ECs,  since  part  of  the  familial
accumulation  of  EC  shown  in  both  pedigree  and  population-based  studies  may
represent atypical HNPCC. Familial site-specific endometrial carcinoma is also
reported to form a separate entity, but its genetic basis is still unknown. In
general, little is known about the molecular background of endometrial
tumorigenesis compared to tumor development in the colon. We found 9% of
families with familial site-specific EC (in the absence of any associated clustering
of other cancers) to be due to germline mutations in the MMR genes. We observed
that the simultaneous presence of CRC in the family seems to be a somewhat
stronger predictor of MMR gene germline mutations. We studied the role of
PI3K/AKT pathway in familial ECs as well and observed that PIK3CA
amplifications are characteristic of familial site-specific EC without MMR gene
germline mutations. Most of the high-level amplifications occurred in tumors
with stable microsatellites, suggesting that these tumors are more likely
associated with chromosomal rather than microsatellite instability and MMR
defect.
Despite advances in deciphering the molecular genetic background of HNPCC, it
is poorly understood why certain organs (such as the colorectum and
endometrium) are more susceptible than others to cancer development. To clarify
whether the mechanisms of MMR gene inactivation play a role in selective organ
susceptibility we tested loss of heterozygosity (LOH) and methylation in HNPCC
colorectal versus endometrial tumorigenesis. The idea was based on the fact that
although a MMR gene mutation is dominant, the phenotype of a mutation carrier
is  normal  in  the  beginning.  A somatic  mutation is  needed to  inactivate  the  wild
type allele before multi-step carcinogenesis can start. We observed that LOH and
methylation  targeted  the  wild  type  allele  differently  in  CRC  and  EC  and  the
pattern of these somatic events was dependent on the predisposing germline
mutation. We conclude that somatic second hits may in part explain the
differential tumor susceptibility of different organs in HNPCC.
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Precise molecular characterization of families with clustered cancers of the
colorectum and endometrium is highly relevant for the proper genetic counseling
and clinical management. Furthermore, since the same genes are often involved in
familial and sporadic tumorigenesis, our observations in familial CRC and EC are
likely to benefit the research done on sporadic cancers as well.
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REVIEW OF THE LITERATURE
1. Characteristics of cancer
Cancer is a major public health problem, especially in the western world. In 1953,
the Finnish Cancer Registry began registering all suspected or diagnosed cancer
cases  in  Finland  and  since  that  time  the  cancer  incidence  has  increased
continuously  (The  Finnish  Cancer  Registry,  Cancer  statistics  at
www.cancerregistry.fi last updated on Sept 20th 2006). At the moment every
fourth Finn is diagnosed with cancer during their lifetime (The Finnish Cancer
Registry, Cancer statistics at www.cancerregistry.fi last updated on Sept 20th
2006). Luckily cancer diagnostics and treatments have improved and more than a
half of cancer patients can be cured (Finnish Cancer Organisations at
www.cancer.fi).
Cancer is not one single disease, but a name for many diseases with uncontrolled
cell growth, and invading and immortal cells as common features (Hanahan and
Weinberg 2000). Cancer diseases are grouped into different types according to the
tissue they arise from. Carcinomas are derived from the epithelia, sarcomas from
the  mesenchyme,  leukemias  and  lymphomas  from  blood-forming  tissues,  and
various cancers of the nervous system from the neuroectoderm (Weinberg 2007a)
Cancers are typically named after the organ they affect, such as breast cancer,
colorectal cancer and endometrial cancer.
Environmental factors, including lifestyle, cause the majority of human cancers
(Boffetta 2006). The risk factors associated with the development of cancer are
numerous and complex (Shields and Harris 1991). It is often difficult to point out
a single cause of a cancer, but certain environmental factors have strong
correlation  with  the  occurrence  of  particular  cancers.  It  has  been  observed  for
example that there is a clear correlation between smoking and lung cancer
(Brennan et al. 2006).  In  Finland,  about  90% of  lung cancers  are  due to  smoking
(Syöpäjärjestöt, Tietoa syövästä at www.cancer.fi). Most of the cancers arise due
to complex interactions between environmental factors and genes (Potter 1999),
and the proportion of environmental and genetic effect varies between different
cancers. Cancer formation is a multistage process and environmental factors can
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affect any stage through genetic and epigenetic mechanisms (Shields and Harris
1991).
Practically every cell contains very similar molecular machinery to control
growth, proliferation, differentiation, and death. Tumorigenesis is a process in
which  this  machinery  fails  to  maintain  cell  integrity  and  finally  leads  to  cancer.
This  process  includes  six  essential  alterations  in  cell  physiology,  including  self-
sufficiency in growth signals, insensitivity to anti-growth signals, evasion of
apoptosis, limitless replicative potential, sustained angiogenesis, and tissue
invasion and metastasis (Hanahan and Weinberg 2000). These six changes can
occur in variable order and in parallel.
1.1 Cancer genetics
Cancer is a genetic disease since most of the above mentioned six essential
changes  are  acquired  directly  or  indirectly  through  changes  in  the  genome.  An
estimated three to seven mutations, usually in four to five different genes, are
needed for  cancer  formation,  depending on cancer  type (Vogelstein  and Kinzler
2002a). Mutation rate in a tumor cell at the beginning of tumorigenesis is probably
the  same  as  in  normal  cells.  The  selective  conditions  in  the  tumor  environment,
such as aberrant cell-cell interactions, however, are different from those in the
environment of normal cells. The selective advantage in the tumor environment,
provided by a mutation in a growth control gene, may give rise to clonal
expansion, allowing the tumor cell with the mutation to overtake its sister cells.
Cancer can arise by a variety of genetic alterations including point mutations,
amplifications, deletions, insertions, and changes in chromosome number and
chromosomal translocations (Lengauer et  al. 1998). Only approximately 5% of
such  genetic  alterations  are  present  in  the  germline  and  evidently  cause  a
hereditary cancer (Vogelstein and Kinzler 2002a). Most mutations are somatic,
affecting only the neoplastic cells. Thus the expression “cancer is a genetic
disease” means that tumorigenesis is driven by altered genes. Most of these
alterations are sporadic.
Cancer related genes can be classified into two groups that have opposite effects
in normal cell function. Oncogenes normally stimulate cell growth and become
hyperactivated in cancer, whereas tumor suppressor genes mainly repress cell
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growth  in  the  normal  situation  but  are  inactivated  in  cancer  cells.  The  main
differences between oncogenes and tumor suppressor genes are presented in
Table 1, on page 16.
1.1.1 Oncogenes
The first cancer genes discovered were derived from cancer-causing viruses.
These genes became called oncogenes as they are capable of causing oncogenesis
(Vogelstein and Kinzler 2002b). It was observed that viral oncogenes have cellular
equivalents, which when mutated cause cancer in dominant manner. At the
moment over one hundred cancer related oncogenes are known (Futreal et  al.
2004). These oncogenes function in normal cells in different ways to increase cell
growth, proliferation and differentiation, and to decrease cell mortality.
Oncogenes can be classified according to their protein products, which are growth
factors, growth factor receptors, transcription factors, signaling proteins, and cell
cycle regulators. Majority of altered oncogenes cause sporadic cancers and only
few inherited cancer susceptibilities caused by oncogenes are currently known
(Table 1).
1.1.2 Tumor suppressor genes
The idea of a recessive cancer gene arose from somatic cell fusion hybridization
experiments where mouse A9 cells were capable of suppressing tumorigenesis in
malignant cells (Harris et  al. 1969). These recessive cancer genes are known as
tumor suppressors. The normal function of a tumor suppressor gene is to inhibit
cell proliferation. Protein products of tumor suppressor genes participate in DNA
repair, growth regulation, and differentiation. In 1971, AJ Knudson was the first
to show (Knudson 1971) that human tumor suppressor genes exist and since then
over  30  tumor  suppressor  genes  with  cancer  predisposing  mutations  have  been
found. Most of the inherited cancer susceptibilities are due to alterations in tumor
suppressor genes. The same genes are also altered in the corresponding sporadic
cancers (see Table 1).
By studying retinoblastoma Knudson (1971) discovered that familial cases were
much  more  likely  to  get  bilateral  disease  compared  to  sporadic  cases,  and  they
developed cancer at an earlier age. These observations led to Knudson’s two hit
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theory (Figure 1):  two hits,  or mutagenic events,  in a tumor suppressor gene are
necessary for cancer development. In the hereditary form of cancer one mutation
(the first hit) is inherited and a second mutation (the second hit) occurs in somatic
cells, while in the non-hereditary form two mutations must occur somatically for
cancer development. According to this hypothesis, tumor suppressor genes are
recessive at the cellular level since complete loss of function is required to reveal a
cancer phenotype. Germline mutations in tumor suppressor genes function
dominantly at the organism level, however, predisposing the carrier to early onset
of disease by supplying the first hit at birth.
Figure 1 Mechanisms of second hit. M, maternal chromosome with mutant allele;
P, paternal chromosome with wild type allele; I, mitotic nondisjuction
where the whole P chromosome is lost; II, mitotic recombination (or gene
conversion) where the mutated locus replaces the normal locus (or gene);
III, deletion of the normal allele; IV, sporadic mutation in paternal allele;
V, gene silencing by promoter methylation of the wild type allele.
Modified from Aittomaki and Peltomaki (2006).
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Table 1. Features of oncogenes and tumor suppressor genes
Examples  of  genes  addressed  in  the  present  study  are  in  bold.  *The  same  tumor  suppressor  genes  are
frequently altered in both sporadic cancers and inherited cancer syndromes. ABL, v-abl Abelson murine
Features Oncogene Tumor suppressor gene
Normal function Growth stimulation Growth repression




Dominant  at cellular level:  Activation of
one allele is sufficient for transformation
Germline mutation in one allele leads to
dominantly inherited cancer
predisposition in family
Recessive at cellular level: Both alleles
need to be inactivated before
transformation
Germline mutation in one allele leads to
dominantly inherited cancer
predisposition in family (few exceptions)
Mutation
mechanism
Point mutation (KRAS, CTNNB1,
PIK3CA)
Amplification (PIK3CA)
Chromosomal rearrangement leading to
chimeric gene (BCR-ABL) or to oncogenic
activation  (IGH-MYC)
Point mutation, both inherited and
somatic events (MMR genes, PTEN)
Large rearrangements leading to gene
deletion or duplication, both inherited and
somatic events
Loss of heterozygosity (MMR genes),
somatic events





Altered in multiple sporadic cancers
KRAS – colorectal and thyroid cancer,
acute myeloid leukemia,  melanoma
PIK3CA – colorectal, gastric, ovarian,
breast, endometrial cancer
PDGF – gliomas, sarcomas
ERBB2/HER/NEU – breast cancer,
neuroblastoma






ABL  - chronic myelogenous leukemia
Predisposition to only few known cancer
syndromes
RET – multiple endocrine neoplasia type
2A and 2B
MET – hereditary papillary renal cell
carcinoma
CDK4 – familial melanoma
Altered in multiple sporadic cancers*
Rb1 – retinoblastoma, osteosarcoma
BRCA1 – ovarian carcinoma
TP53 – most frequently altered gene in
multiple cancers
APC – colorectal cancer
MLH1 – colorectal and other carcinomas
VHL – renal cell carcinoma,
hemangioblastoma
PTEN – endometrial and other carcinomas
Predisposition to more than 20 cancer
syndromes*
Rb1 – hereditary retinoblastoma
BRCA1 – hereditary breast and ovarian
cancer
TP53 – Li-Fraumeni syndrome
APC – familial adenomatous polyposis coli
MLH1 – hereditary nonpolyposis
colorectal cancer
VHL – Von Hippel-Lindau syndrome
PTEN – Cowden syndrome
FH – hereditary uterine leiomyomas and
renal cell carcinoma
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leukemia viral oncogene homolog 1; APC, adenomatous polyposis coli; BCL2, B-cell lymphoma gene-2; BCR, breakpoint
cluster region; BRCA1, breast and ovarian cancer gene 1; CDK4, cyclin dependent kinase 4; CTNNB1, -catenin gene;
ERBB2/HER/NEU, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2; FH, fumarate hydratase; FOS, v-fos FBJ
murine osteosarcoma viral oncogene homolog; JUN, JUN oncogene; IGH, immunoglobulin heavy locus; KIT, v-kit
Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; KRAS, Kirsten rat sarcoma viral oncogene homolog; MET,
proto-oncogene tyrosine kinase; MLH1, human mutL homolog 1; MMR, mismatch repair; MSH2, human mutS
homolog 2; MSH6, human mutS homolog 6; MYC, v-myc avian myelocytomatosis viral oncogene homolog;  PDGF,
platelet-derived growth factor; PIK3CA, phosphatidylinositol 3-kinase catalytic subunit alpha gene (p110 ); PTEN,
phosphatase  and  tensin  homolog;  Rb1,  retinoblastoma  1;  RET,  RET  oncogene;  TP53,  tumor  protein  p53;  VHL,  von
Hippel-Lindau tumor suppressor. Modified from Aittomaki and Peltomaki (2006).
Tumor suppressor genes are divided into three groups, namely gatekeepers,
caretakers (Kinzler and Vogelstein 1997), and landscapers (Kinzler and Vogelstein
1998). The role of gatekeepers is to regulate cell growth by directly inhibiting the
growth or by promoting cell death. Since gatekeeping genes are rate-limiting for
tumor initiation, mutations in these genes can occur somatically as well as in the
germline. The activity of gatekeepers varies between different tissues leading to
tissue specificity in cancer predisposition (Kinzler and Vogelstein 1997). For
example, mutation in the Rb1 gene leads to retinoblastoma whereas mutant NF1
predisposes to cancer of Schwann cells.
Caretakers form a class of genes that, when inactivated, do not directly promote
tumors. Instead their inactivation results in genetic instability causing an
increased mutation rate affecting all genes, including other tumor suppressor
genes and oncogenes, and in that way promote tumor formation. Examples of
caretaker genes are the mismatch repair (MMR) genes that predispose to
colorectal and endometrial cancer, and the BRCA1 and BRCA2 (Hall et  al. 1990;
Narod et al. 1991; Wooster et  al. 1994)  in  which  mutations  lead  to  breast  cancer
predisposition. Consequently, mutations in caretaker genes as well as in
gatekeeper genes lead to very specific tissue distribution of cancer.
Landscaper  genes  affect  tumorigenesis  indirectly  by  changing  the
microenvironment to support tumor formation. For example in Juvenile
polyposis,  hamartomatous  polyps  seem  to  develop  into  cancer  through  the




The normal mutation rate in a somatic cell is approximately 1x10-10 mutations per
base pair per generation (Kunkel and Bebenek 2000). This would provide less
than  one  random  mutation  in  every  cell  cycle.  Such  a  slow  mutation  frequency
would only  generate  one mutant  gene in  each cell  of  a  human being during the
lifetime. A variety of experiments show, however, that a cancer cell may contain
as many as 10000-100000 mutations (Stoler et al. 1999). One explanation for such
an accumulation of  mutations  can be  genetic  instability.   In  fact,  nearly  all  solid
tumors are genetically unstable (Lengauer et al. 1998; Struski et  al. 2002). In most
cancers the instability is observed at the chromosomal level (chromosomal
instability, CIN) but in a small subset of cancers the instability is detected at the
nucleotide level (microsatellite instability, MSI) (Lengauer et al. 1998). In general,
an  inverse  relationship  between  CIN  and  MSI  exists.  Cancers  showing  MMR
deficiency (leading to MSI) are usually diploid and cancers with proficient MMR
function are usually aneuploid (Lengauer et al. 1997).
1.2.1 Chromosomal instability
Chromosomal  instability  has  been  considered  to  result  from  losses  and  gains  of
whole chromosomes or large portions of them (Michor et  al. 2005). Recently the
term CIN has got a broader meaning. It has been shown that CIN can also occur
without changes in copy number (Gaasenbeek et  al. 2006). It is accompanied by
structural abnormalities, such as translocations, and by numeral changes of
chromosomes, known as aneuploidy. Aneuploidy is present in almost all
epithelial cancers (Struski et  al. 2002) and results from gains or losses of whole
chromosomes. Lost chromosomal regions may contain tumor suppressor genes
and gains may alter the gene expression patterns, and together these changes lead
to optimal tumor growth. Thiagalingam et al. (2001) has proposed a two-step
model for aneuploidy. The first step involves defects that lead to abnormalities in
chromosome number in the absence of structural changes and the second defect
presumably results in a higher frequency of structural changes in chromosomes
associated with interchromosomal recombination.
Translocations are structural abnormalities that are present in many different
tumors but they can also lead to specific neoplastic diseases, such as leukemias
and lymphomas. An example of a specific chromosomal translocation is the
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formation of the Philadelphia chromosome, in which part of the BCR gene from
chromosome 22q11 is fused with part of the ABL gene on chromosome 9q34. This
oncogenic fusion protein is found in 90% of chronic myelogenous leukemia
patients (Kurzrock et  al. 2003). Such disease specific translocations are very rare
events among all cancers, since most cancers show nearly random translocations
(Johansson et al. 1996). A recent publication showed, however, that recurrent gene
fusions of TMPRSS2 and ERG or ETV1 transcription factor genes occur in prostate
cancer (Tomlins et  al. 2005). Translocations can lead to oncogenic fusion proteins
as described above, or a tumor suppressor gene might get inactivated by
disruption.
A large number of genes with alterations can give rise to CIN. These genes
include those involved in chromosome condensation, sister-chromatin cohesion,
kinetochore structure and function, and centromere/microtubule formation and
dynamics, as well as cell cycle checkpoint genes (Elledge 1996; Murray 1995;
Paulovich et  al. 1997).  This  might  explain  why CIN is  a  very common feature  in
many cancer types (Struski et  al. 2002). Although the molecular background of
CIN  is  not  completely  known,  it  may  only  require  a  single  mutational  hit  to
produce the phenotype (Lengauer et al. 1997). So far, however, this notion has
been difficult to prove.
Loss of heterozygosity
Chromosomal instability can be detected as loss of heterozygosity (LOH). LOH,
that is loss (or reduction of the relative dosage) of one of the two parental alleles
(Cavenee et  al. 1983), can occur either by physical deletion of all copies of the
respective allele or by mechanisms that do not affect the net gene dosage
(Gaasenbeek et al. 2006). LOH is also sometimes called an allelic imbalance since it
is more often observed as a decreased dosage of one allele rather that a complete
loss of one allele. LOH, like CIN, is a very broadly used term describing the loss
of heterozygous alleles producing a tumor with increasing homozygosity.
Different mechanisms that can lead to loss of heterozygosity are seen in tumors:
deletion of a chromosome segment, mitotic nondisjunction, homologous
recombination, nonhomologous recombination leading to translocation, break-
induced replication, and gene conversion (Cavenee et  al. 1983; Gaasenbeek et al.
2006; Mei et  al. 2000; Rowley 2005; Thiagalingam et al. 2001).  The mechanisms
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behind LOH have been shown to be, to some extent at least, chromosome-specific
(Gaasenbeek et al. 2006; Thiagalingam et al. 2001) with some chromosomes having
a tendency to show complete loss and others displaying partial losses. In addition,
some cancers tend to harbor loss and regain of whole-chromosome or mitotic
recombination (Gaasenbeek et  al. 2006). Overall, LOH is widespread in many
tumors (Gaasenbeek et al. 2006; Vogelstein et al. 1989).
1.2.2 Microsatellite instability
Compared to CIN, microsatellite instability (MSI) is a feature of a smaller subset
of cancers (Boland et  al. 1998). The instability is seen at the nucleotide level,
including single base substitutions, and insertions and deletions of a few
nucleotides (Jiricny 1998). Microsatellites are short tandem repeats of DNA
sequence scattered throughout the genome (Weinberg 2007b). The repeated
sequence is often simple, consisting of two to four nucleotides (di-, tri-, and
tetranucleotide repeats) (Buermeyer et al. 1999), and can be repeated 10 to 100
times. Microsatellites owe their variability to an increased rate of mutation
compared to other neutral regions of DNA. These high rates of mutation are often
caused by slippage of the DNA polymerase during DNA replication (Buermeyer
et al. 1999; Kolodner and Marsischky 1999; Kunkel 1990). Most of the errors in
slippage are corrected, but some mutations can escape repair (Buermeyer et al.
1999; Kolodner and Marsischky 1999; Kunkel 1993). Microsatellites are said to be
unstable  when  the  germline  allele  has  gained  or  lost  repeat  units.  Such  an
alteration can be detected only if many cells are affected by the same change. Thus
it can be used as an indicator of clonal expansion typical of a neoplasm (de la
Chapelle 2003).
While  the  molecular  background  of  the  CIN  phenotype  is  poorly  known,  the
molecular mechanisms behind MSI are well characterized. MSI is caused by
defects  in  the  DNA  MMR  mechanism  responsible  for  the  fidelity  of  DNA
replication (Jiricny 1998).  MMR proteins repair base-base mismatches and small
insertion-deletion loops generated by the DNA polymerase during replication
(Jiricny and Nystrom-Lahti 2000). The key components of MMR are highly
conserved from bacteria to mammals, and the knowledge of the human system is
mainly based on the observations made in Saccharomyces cerevisiae (Jacob and Praz
2002). At least six different MMR proteins are needed in humans to ensure the
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fidelity of DNA replication (Peltomaki 2001). MMR proteins form specific
heterodimers with each other, depending on the type of the mutation to be
corrected (Figure 2). If the mutation to be corrected is a base-base mispair the
MSH2 protein functions as a complex with MSH6. The MSH2 protein may co-
operate with MSH3, in addition to MSH6, if an insertion-deletion loop is to be
repaired (Peltomaki 2003), since MSH3 and MSH6 have partially redundant
functions in insertion-deletion loop repair (Das Gupta and Kolodner 2000;
Marsischky et  al. 1996). MLH1 protein forms a heterodimer with PMS2 to
coordinate the interplay with the mismatch recognition complex and other
proteins necessary for MMR (Peltomaki 2001), primarily in the repair of insertion-
deletion loops. MLH1 may also heterodimerize with MLH3 and PMS1. MLH3
contributes to the correction of insertion-deletion loops (Lipkin et al. 2000), but the
role of PMS1 in MMR is not yet clear (Leung et al. 2000).
Figure 2 MMR protein complexes during repair. Upper heteroduplex shows two
different errors; base/base mispair and two nucleotide insertion loop.
Both of these errors can be repaired by the MSH2/MSH6-MLH1/PMS2
complex. Insertion loops can also be repaired by the MSH2/MSH3-
MLH1/PMS2 complex and by the MSH2/MSH3-MLH1/MLH3 complex.
In all cases the repair process is directed at the primer strand with nicks.
Solid arrows denote the main repair pathways and the dashed arrow the
secondary pathway.  Modified from Jiricny and Nystrom-Lahti (2000).
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A  defective  MMR  system  results  in  a  mutator  phenotype  and  unstable
microsatellites. The mutation rate in MMR deficient tumor cells is 100-1000-fold
that of normal cells (Bhattacharyya et al. 1994; Parsons et al. 1993). Although most
microsatellites  exist  in  non-coding  DNA,  they  are  also  found  in  a  number  of
human  genes.  Such  genes  easily  accumulate  frameshift  mutations  during
replication and in the presence of defective MMR these mutations remain in the
DNA sequence leading to truncated proteins. Genes that are altered in MSI
tumors encode proteins involved in signal transduction (TGF -RII [Parsons et  al.
1995], PTEN [Shin et al. 2001]), apoptosis (BAX [Rampino et  al. 1997]),
transcription regulation (TCF-4 [Duval et al. 2000]) and DNA repair (MSH6,
MSH3 [Ohmiya et al. 2001]).  In addition to MSI, MMR defect leads to genomic
instability  manifesting  as  LOH,  chromosomal  translocations,  and  gene
conversions, since MMR proteins function besides post-replicative repair in
several other mechanisms that are highly relevant to tumorigenesis (see chapter
4).
Unstable microsatellites, as a manifestation of a MMR defect, occur in
approximately 15% of sporadic colorectal tumors (Boland et al. 1998), and in over
90% of HNPCC tumors (Aaltonen et al. 1993). A majority of sporadic colon
cancers with a high degree of MSI are caused by the inactivation of MLH1, which
mostly results from biallelic promoter hypermethylation (Veigl et al. 1998). In
HNPCC, germline mutations in MMR genes accompanied by somatic inactivation
of the wild-type allele by different mechanisms lead to a varying degree of MSI in
tumors (discussed in chapter 2.1).
1.3 Cancer epigenetics
Gene expression changes that do not involve alterations in DNA sequence are
called epigenetic changes. Epigenetic changes are mainly inherited through
mitosis  and  thus  passed  from  parental  cell  to  daughter  cells.  Epigenetic
mechanisms that influence DNA expression include histone modifications and
methylation of cytosines located within the CpG dinucleotides (Geiman and
Robertson 2002). Approximately 70% of CpG dinucleotides are methylated in the
human genome, whereas most of the unmethylated CpGs are located in CpG
islands (Bird 1986). CpG islands are present in around 50% of mammalian genes
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(Antequera and Bird 1993), usually located close to the transcription start site.
Certain CpG islands are normally methylated, including imprinted genes, X-
chromosomal genes in women, germline specific genes, and tissue specific genes
(Baylin et al. 1998).
The aberrant epigenetic profile of a cell can contribute to cancer development.
Hypermethylation of a promoter CpG island attracts chromatin inactivating
complexes and may prevent transcription factors from binding, thus silencing the
respective gene (Lopez-Serra et al. 2006; Richardson 2003). A lot of evidence
suggests  that  epigenetic  silencing  of  a  tumor  suppressor  gene  is  a  frequent
mechanism of gene inactivation (Costello et al. 2000; Esteller et al. 2001; Esteller
2002; Herman and Baylin 2003; Myohanen et al. 1998). For example, although
germline mutations in MLH1 strongly predispose to HNPCC, in sporadic
colorectal cancers MLH1 silencing by epigenetic mechanisms (methylation) occurs
at a much higher rate than mutational inactivation (Cunningham et  al. 1998;
Herman et al. 1998; Veigl et al. 1998). Table 2 shows some examples of genes found
to be hypermethylated in human cancers.
Table 2. Examples of hypermethylated genes in human cancers
Cancer Methylated genes Consequence Reference
Colorectal cancer MLH1 Mutator phenotype (Herman et al. 1998)
Endometrial cancer PTEN Excessive cell invasion (Salvesen et al. 2001)
Gastric cancer MGMT Mutator phenotype (Hong et al. 2005)
Ovarian cancer p16 Extended lifespan of a cell (Wiley et al. 2006)
Breast Cancer ER Transcriptional repression of target genes (Li et al. 2006)




MLH1, human MutL homolog 1; PTEN, phosphatase and tensin homolog; MGMT, O-6-methylguanine-
DNA methyltransferase; p16, Cyclin-dependent kinase inhibitor-2A; ER, estrogen receptor; GSTP1,
glutathione-S-transferase 1
Aberrant methylation in cancer cells includes, besides gene specific
hypermethylation, global DNA hypomethylation. A cancer cell can have 20-60%
fewer methylated cytosines than a normal cell (Lapeyre and Becker 1979; Lu et al.
1983). Hypomethylation contributes to carcinogenesis mainly through repetitive
sequences,  although  growing  evidence  also  exists  for  gene  specific  alterations
(Table 3). Decreased DNA methylation in a cell can lead to loss of imprinting,
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LOH, and aneuploidy, as well as reactivation of transposable elements (Esteller
and Herman 2002). For example in colon carcinoma, progressive hypomethylation
of LINE-1 correlates with multistage carcinogenesis from normal epithelium to
late stage carcinoma (Chalitchagorn et al. 2004).
Table 3. Examples of hypomethylated genes in human cancers
Cancer Hypomethylated  genes Consequence Reference
Colorectal cancer MAGE A1 and A3 Promotion of growth (Kim et al. 2006)
Gastric carcinoma CCND2 Continuous proliferation (Oshimo et al. 2003)
Ovarian carcinoma SNCG Increased proliferation and
metastasis
(Gupta et al. 2003)
Breast cancer uPA Promotion of growth and invasion (Guo et al. 2002)
Pancreatic cancer maspin Increased invasiveness (Fujisawa et al. 2005)
Bladder cancer EGR1 Degradation of extracellular matrix
and cell membrane
(Ogishima et al. 2005)
MAGE, melanoma associated antigen; CCND2, cyclin D2; SNCG,  synuclein ; uPA, urokinase-type
plasminogen activator; maspin, protease inhibitor 5; EGR1, early growth response gene 1
2. Colorectal cancer
Colorectal cancer is the third most common cancer in Finland, right after prostate
and breast cancer. Over 2200 new cases are diagnosed yearly and around 1000
patients  die  of  CRC  (The  Finnish  Cancer  Registry,  Cancer  statistics  at
www.cancerregistry.fi last updated on Sept 20th 2006). The same trend can be seen
in all western countries. Risk factors for CRC include environmental factors such
as low-fibre – high-fat diet, sedentary lifestyle, smoking, high alcohol
consumption, obesity and diabetes mellitus, and personal or family history of
cancer  of  the  small  bowel  (and large  bowel  in  a  family  member),  endometrium,
breast, or ovary (Weitz et  al. 2005). In general, CRC is a disease of elder people
(mean age at onset around 70 years), but hereditary CRCs occur at a much
younger age at onset (45 years in HNPCC) (Lynch and de la Chapelle 1999).
Approximately 70% of all CRCs are sporadic, occurring by chance or caused by
environmental factors, and 25-30% are due to some kind of inherited
predisposition  (Figure  3).  No  more  than  ~5%  of  such  CRCs  are  inherited  as  an
obvious mendelian trait and are due to highly penetrant mutations in a single
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gene, while the rest (~25%) are not associated with clear mendelian families
(Rowley 2005). In addition to high penetrance susceptibility genes a number of
low penetrance susceptibility genes largely affect the overall risk for CRC (Abdel-
Rahman and Peltomaki 2004), whether familial or sporadic. Furthermore,
modifier genes and environmental factors bring additional variability to cancer
susceptibility (de la Chapelle 2004).
Figure 3 Proportion of inherited susceptibility to colorectal cancer. Hereditary
nonpolyposis colorectal cancer accounts for approximately 3-5%
(Aaltonen et al. 1998; Mecklin 1987; Rodriguez-Bigas et al. 1997; Salovaara
et al. 2000; Scapoli et al. 1994) and familial adenomatous polyposis coli for
0.5-1.5% (Bisgaard et al. 1994)  of  all  CRCs.  Other  polyposis  syndromes
include for example hamartomatous polyposis syndromes, and they
account together less than 1% of all CRCs (Burt and Neklason 2005).
Around  20-25%  of  CRCs  occur  in  individuals  with  a  positive  family
history and can therefore be considered to have some inherited
susceptibility (de la Chapelle 2004; Lynch and de la Chapelle 2003).  The
rest ~70% of CRCs are considered to be sporadic (de la Chapelle 2004;
Lynch and de la Chapelle 2003).
Colorectal cancer is probably the most studied cancer type and is used as a model
for tumorigenesis of other epithelial cancers. CRC is rather easy to study, since the
different stages of CRC are quite easily accessible and there are well-defined
inherited susceptibilities to CRC. Studies on hereditary CRC syndromes are
valuable for the characterization of the respective sporadic CRCs, since the same
genes and pathways are affected in both. The most commonly affected pathway
in  colorectal  carcinogenesis  is  the  Wnt  pathway  (Huang et  al. 1996; Morin et  al.
1997; Rowan et  al. 2000). Germline mutations in the APC gene predispose to
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familial adenomatous polyposis (FAP). However, APC is also a very important
gene in sporadic CRCs (Miyoshi et al. 1992; Powell et  al. 1992). Another well
known CRC syndrome, HNPCC, develops through inherited mutations in MMR
genes. The same genes are implicated in around 15% of sporadic colorectal
cancers (Peltomaki 2003). Other very common alterations in CRC are TP53 and
KRAS mutations. TP53 is genetically altered in over 80% of the cases (Baker et al.
1990), and KRAS mutations occur in approximately 30% of colorectal cancers (Bos
et al. 1987). Two major carcinogenetic pathways for colorectal cancer are proposed
to exist. The MSI/CIN- tumors have defective MMR and unstable microsatellites,
and are usually diploid (CIN-). Tumors developed via the MSS/CIN+ pathway
include  gross  changes  in  chromosome  number  (CIN+),  but  exhibit  stable
microsatellites (MSS) (Abdel-Rahman et al. 2001; Lengauer et al. 1997).
Hereditary colorectal cancers can be divided into non-polypotic and polypotic
cancers. Non-polypotic syndromes include HNPCC, Muir-Torre syndrome, and
Turcot’s syndrome (HNPCC variant) (Abdel-Rahman and Peltomaki 2004; Allen
and Terdiman 2003). Familial CRC type X (Lindor et al. 2005) is also non-
polypotic, but its molecular background, to date, is not well characterized.
Polypotic syndromes can be further divided into two classes according to whether
a large number of adenomatous or hamartomatous polyps are present.
Adenomatous polypotic syndromes include FAP, attenuated FAP, Turcot’s
syndrome (APC variant), and MYH-associated polyposis (Abdel-Rahman and
Peltomaki 2004; Allen and Terdiman 2003). Juvenile polyposis, Peutz-Jeghers, and
Cowden syndrome belong to hamartomatous polypotic syndromes (Abdel-
Rahman and Peltomaki 2004; Allen and Terdiman 2003). Two groups of familial
CRCs (HNPCC and Familial CRC type X) are discussed in more detail in the next
two paragraphs.
2.1 Hereditary nonpolyposis colorectal cancer
HNPCC is a well-characterized hereditary cancer syndrome. It is the most
common form of hereditary colorectal cancers, comprising around 4% of all CRCs
(Figure 3). The average age at onset for CRC among HNPCC patients is 45 years
(Lynch and de la Chapelle 1999), which is around 20 years earlier than in sporadic
colorectal cancer. Predisposed individuals have a 75-80% lifetime risk of
developing CRC (Aarnio et al. 1999; Lynch and de la Chapelle 1999), but they are
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also at an increased risk for extracolonic carcinomas. Lifetime risk for endometrial
carcinoma (EC) is 50% in predisposed females, and risk for cancer of the stomach,
small intestine, ovary, pancreas, ureter, and renal pelvis is less than 15% in
individuals with HNPCC predisposition (Aarnio et  al. 1995; Watson and Lynch
1993).
HNPCC colorectal cancers are predominantly associated with the proximal colon,
are poorly differentiated or show mucinous or signet-ring differentiation, and are
relatively non-aggressive (Jass et al. 1994). Since no clear pathologic features (like
hundreds of adenomas as in FAP) by which HNPCC could easily be identified
exist, diagnosis was mainly based on individual patient and family history of
cancer, until the criteria for HNPCC diagnostics were established. These criteria,
called Amsterdam criteria I, (Table 4) were first defined in 1990 by the
International Collaborative Group on HNPCC, and they only accept CRC as a
manifestation of HNPCC (Vasen et al. 1991). The criteria were then revised in 1998
as the Amsterdam criteria II (Vasen et al. 1999), which also include extracolonic
HNPCC associated cancers. In addition to these two criteria, the Bethesda
guidelines (Rodriguez-Bigas et  al. 1997) were developed to help clinicians by
describing  all  clinical  conditions  in  which  there  is  suspicion  of  HNPCC,  even  if
the respective family does not fulfill Amsterdam criteria. Bethesda guidelines
have also been revised (Table 4) to better suit present day analyses that are very
useful in HNPCC diagnostics (Umar et al. 2004).
Predisposition  to  HNPCC  comes  through  inherited  germline  mutations  in  the
MMR genes: MSH2 (Fishel et  al. 1993; Leach et al. 1993; Peltomaki et al. 1993),
MLH1 (Bronner et  al. 1994; Lindblom et al. 1993; Papadopoulos et  al. 1994;
Tannergard et al. 1994), MSH6 (Akiyama et al. 1997; Miyaki et al. 1997a), and PMS2
(Nicolaides et al. 1994). Most of the known 500 HNPCC associated mutations (The
International Society for Gastrointestinal Hereditary Tumors, Database for
mutations at www.insight-group.org) occur in MLH1, MSH2, and MSH6, whereas
mutations in PMS2 are  rare  and  are  mainly  associated  with  Turcot’s  syndrome
(De Rosa et al. 2000; Hamilton et al. 1995; Miyaki et al. 1997b; Truninger et al. 2005).
With a few exceptions (mainly associated with PMS2 and  Turcot’s  syndrome)
HNPCC is  a  dominantly  inherited cancer  syndrome,  even though at  the  cellular
level, both copies of the respective MMR gene need to be inactivated before the
multistep tumorigenesis can start.
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Table 4. Diagnostic criteria and guidelines for HNPCC
Amsterdam criteria I and II Bethesda guidelines
1. At least three relatives with HNPCC associated
cancer (in colorectum, endometrium, small bowel,
ureter, renal pelvis)
2. One should be a first degree relative of the other
two
3. At least two affected generations
4. At least one member diagnosed before age 50
5. FAP should be excluded
6. Tumors should be verified by pathological
examination
1. CRC diagnosed in a patient before age 50
2. Presence of synchronous, metachronous CRC or
other HNPCC associated tumors, regardless of age
3. CRC with the MSI-high histology diagnosed in a
patient before age 60
4. CRC diagnosed in one or more first-degree relatives
with an HNPCC associated tumor, with one of the
tumors diagnosed before age 50
5. CRC diagnosed in two or more first- or second-
degree relatives, with HNPCC associated tumors,
regardless of age
MMR  deficiency  in  HNPCC  tumors  (as  well  as  in  sporadic  tumors)  leads  to
unstable microsatellites. This is detected by testing the tumors for five
microsatellite markers comprising the Bethesda panel (Boland et al. 1998). MSI is
scored to be high (MSI-high) if more than two of the Bethesda panel markers are
unstable.  MSI-low  is  a  definition  for  tumors  with  no  more  than  one  unstable
microsatellite marker (Boland et al. 1998). Most of the HNPCC cases with germline
mutation in MLH1 or MSH2 show MSI-high phenotype and fulfill the Amsterdam
criteria I, and are referred to as classical HNPCC families (Liu et al. 1996;
Nystrom-Lahti et al. 1996). Whereas germline mutations in MSH6 can lead to MSI-
high or MSI-low, and such tumors may even show stable microsatellites (Berends
et al. 2002; Hendriks et al. 2004; Wu et al. 1999). These families are usually less
typical HNPCC families, with late onset and frequent endometrial carcinomas.
Findings show that germline mutations in PMS2 can lead to autosomal dominant
HNPCC  with  MSI-high  phenotype  in  families  fulfilling  Amsterdam  criteria  II
(Hendriks et  al. 2006; Worthley et  al. 2005). Germline mutations in MLH1 and
MSH2 lead  to  a  more  severe  HNPCC  phenotype  than  mutations  in  other  MMR
genes,  since  MLH1  and  MSH2  are  necessary  in  all  MMR  complexes  and  the
absence of these proteins results in the instability of their interaction partners
(Peltomaki 2001) (see also Figure 2).
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Germline mutations in MMR genes drive the tumorigenic pathway by causing
accumulation of genetic alterations in the genome. The main target genes are
those containing repetitive tracts within coding sequence, such as TGF RII, which
is mutated in up to 90% of MSI CRCs (Parsons et al. 1995). These target genes
may, in addition to tumor progression, correspond to tissue specificity. For
example, frameshift mutations in TGF RII are characteristic of MSI CRC, but most
endometrial carcinomas with MSI lack these mutations, suggesting a different
route  to  MSI  in  EC  (Kuismanen et  al. 2002). Such tissue specific selection may
provide one possible explanation for tumor spectrum of HNPCC since growth
advantage may be acquired by different genes depending on a tissue type.
Molecular testing for HNPCC is started by analyzing microsatellite markers and
MMR protein expression according to the Bethesda guidelines (Umar et al. 2004).
When  the  MSI-high  phenotype  is  observed  or  if  one  of  the  MMR  proteins  lacks
expression, mutations in MLH1 and MSH2,  or in the gene pinpointed by protein
expression analysis, are searched from the germline. By following these
guidelines, approximately 30-90% of HNPCC families, depending on the
population, can be identified (de la Chapelle 2005; Liu et al. 1996; Nystrom-Lahti
et al. 1996; Renkonen et al. 2003; Salovaara et  al. 2000). However, up to 50% of
families fulfilling the Amsterdam criteria fail to show any mutations in MMR
genes by conventional methods (Abdel-Rahman et al. 2006). Among such families,
testing for hidden mutations, large deletions, and splicing errors may lead to
identification of additional HNPCC families (Renkonen et al. 2003). Still around
30-50% of families with the HNPCC phenotype remain truly mutation negative.
These families will be discussed in the next chapter.
2.2 Familial CRC type X and other MMR proficient colorectal
cancers
The  literature  describing  families  with  nonpolypotic  CRC  is  conflicting.  A  large
proportion of families with nonpolypotic CRC meet the diagnostic criteria for
HNPCC,  and  are  therefore  erroneously  classified  as  HNPCC  despite  the  lack  of
MMR gene germline mutations. Renkonen et al. (2003) showed that some of the
CRC families fulfilling either the Amsterdam or Bethesda criteria (originally
considered to be HNPCC families) and lacking evidence of MMR gene
involvement seem to constitute a clinically and molecularly separate entity. In
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these families the average age at CRC onset is significantly higher and tumors are
more  often  located  in  the  distal  colon  than  in  HNPCC  individuals  with  MMR
gene germline mutations. Moreover, such tumors frequently show MSS
phenotype (Lindor et al. 2005; Llor et al. 2005; Mueller-Koch et al. 2005; Renkonen
et al. 2003). Such families are also reported to show increased incidence for CRC
(Lindor et al. 2005; Llor et al. 2005; Mueller-Koch et al. 2005; Renkonen et al. 2003)
but not for extracolonic carcinomas (Lindor et al. 2005), which is a common
feature of HNPCC families. Moreover, relatives in such families have a lower
incidence of CRC (Lindor et al. 2005; Llor et al. 2005). Lindor et al (2005)
hypothesized that families fulfilling the strict Amsterdam criteria with no MMR
defects include cancers that occur by chance, are related to shared lifestyle, or are
due to genetic defects that need to be defined. This heterogeneous group of
familial CRCs is nowadays known as familial CRC type X (Lindor et  al. 2005),
describing the lack of understanding of the etiology behind these families, which
are not necessarily displaying hereditary CRC.
3. Endometrial cancer
Endometrial  cancer  (EC)  is  the  third  most  common  cancer,  after  breast  and
colorectal cancer, in Finnish females. Approximately 800 new cases are diagnosed
every year (The Finnish Cancer Registry, Cancer statistics at
www.cancerregistry.fi last updated on Sept 20th 2006), but the curability is mostly
very high. Endometrial cancer affects mainly perimenopausal or postmenopausal
women, hence 95% of ECs are diagnosed in females over 50 years of age and 58%
in females over 65 (The Finnish Cancer Registry, Cancer statistics at
www.cancerregistry.fi last updated on Sept 20th 2006). The incidence of EC is
increasing slightly, mainly due to population aging. Familial syndromes with a
much lower age at onset of EC, however, also occur (discussed in the next
paragraphs). An estimated 5% of patients with EC diagnosed younger than 55
have a family history of this cancer (Gruber and Thompson 1996). Known risk
factors for EC include estrogen replacement therapy, early menarche, late
menopause, nulliparity, obesity, hypertension, and diabetes mellitus (Henderson
and Feigelson 2000; Hinkula et  al. 2002; Lynch et  al. 1994; McPherson et al. 1996).
In addition, positive personal or family history of breast, ovarian, or colorectal
cancer is a risk factor for EC (Gruber and Thompson 1996; Hemminki et al. 2004;
Suomi et al. 1995).
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The change from a normal endometrium to carcinoma is thought to involve a
stepwise accumulation of alterations in regulatory pathways leading to abnormal
cell growth (Enomoto et al. 1991), as it has been described for CRC. Unlike in CRC,
however, the molecular basis of EC remains poorly known. Endometrial
carcinomas can be classified into two broad categories. Type I consisting of ECs
with endometrioid histology, and Type II including uterine serous carcinomas
(Bokhman 1983). In addition to pathological characteristics, these two types differ
from each other by genetic alterations. Type I tumors are commonly associated
with abnormalities in the MMR genes (Risinger et  al. 1997; Salvesen et  al. 2000),
KRAS (Enomoto et al. 1991; Lax et al. 2000), PTEN (Mutter et al. 2000; Risinger et al.
1997), and CTNNB1 (Kariola et al. 2005; Machin et al. 2002). Type II tumors mainly
show alterations in TP53 (Kounelis et al. 2000; Zheng et al. 1996).
3.1 Endometrial cancer as a part of known syndromes
Approximately 90% of endometrial cancers occur sporadically and only 10% are
considered familial (Boltenberg et  al. 1990). The majority of endometrial
carcinomas recognized as inherited occur in affected women belonging to
HNPCC families. Notably, EC is the most common extracolonic cancer in HNPCC
families (Watson and Lynch 1993) and the risk for EC equals or exceeds the risk
for CRC in females (Aarnio et al. 1999; Dunlop et al. 1997). Females with HNPCC
have a ten-fold increased lifetime risk of EC compared to the general population
(Dunlop et  al. 1997).  HNPCC  is  due  to  germline  mutations  in  the  MMR  genes,
mainly in MLH1, MSH2, and MSH6 (see chapter 2.1). Risk for EC among females
in  such  families  varies  according  to  the  predisposing  mutation  in  the  family,
MSH6 mutation carriers having the highest risk. Wijnen et al. (1999) and Hendriks
et al. (2004) have reported about an excess of EC in female carriers of MSH6
mutations,  the  frequency  and  the  cumulative  risk  for  EC  by  age  of  70  being
around 70%, exceeding the 30% risk for CRC. The average age of onset for EC in
affected HNPCC females is 50 years (Peltomaki et  al. 2001) which is significantly
lower than in sporadic cases (66 [Ylikoski and Komulainen 1999]). Almost all
HNPCC associated ECs show endometrioid histology. When compared to
sporadic ECs, HNPCC associated ECs more frequently show poor differentiation,
Crohn-like lymphoid reaction, lymphangioinvasive growth, and more tumor-
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infiltrating lymphocytes (van den Bos et al. 2004). The spectrum of ECs in women
with HNPCC is wide, however, including tumors of all grades and histologies.
HNPCC associated ECs are diagnosed, like CRCs, according to the Amsterdam
and Bethesda criteria followed by testing tumors for microsatellite instability and
MMR protein expression (see chapter 2.1 for further details). MSI is demonstrated
in HNPCC ECs, but in a lower proportion than in HNPCC associated CRCs, and
the MSI pattern is more heterogeneous (Kuismanen et al. 2002). Unlike in HNPCC
associated CRCs with unstable microsatellites, TGF RII seems not to be a target
loci  in  endometrial  tumorigenesis,  even  though  ECs  show  MSI.  Instead,
frameshift mutations in PTEN associate with MSI ECs (Kuismanen et  al. 2002).
This implies that the genesis of ECs occurs by a route distinct from CRCs, even if
driven by MMR defect.
Germline mutations in PTEN predispose to hamartoma tumor syndrome, namely
Cowden syndrome. Cowden syndrome mainly affects breast, thyroid, uterus,
brain, and mucocutaneus tissues (Starink et al. 1986). Risk for EC is around 5-10%
(Eng 2000) among affected females with Cowden syndrome.
3.2 Familial site-specific endometrial carcinoma
In  addition  to  known  hereditary  cancer  syndromes  with  endometrial  carcinoma
associated with other cancers, occasional families show clustering of EC alone.
Familial  clustering of  EC only,  without  clustering of  any other  cancers,  is  called
familial site-specific endometrial carcinoma (Sandles et  al. 1992). It is unclear
whether such a syndrome truly exists on a molecular level or if it is a
manifestation of other syndrome(s) with EC as a component.
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4. MMR pathway in cancer
The main role of the MMR system is in post-replication repair of single-base
substitutions and small insertion-deletion loops made by DNA polymerase that
have escaped the proofreading. The “mutator phenotype” and MSI resulting from
the failure of this repair function have been discussed above. In addition to post-
replicative repair, MMR proteins have several other functions that are highly
relevant to carcinogenesis. During homologous recombination the MMR system
prevents homeologous recombination between diverged sequences (Chen and
Jinks-Robertson 1999) and thus evades chromosomal translocations,
amplifications, deletions, or insertions. MMR proteins are also involved in
double-strand break repair together with NER enzymes Rad1-Rad10 (Sugawara et
al. 1997). Some MMR components participate in the recognition of DNA adducts
and damaged bases in the DNA structure. This leads to initiation of the signal
pathway that can activate cell-cycle check points and trigger apoptosis (Hickman
and Samson 1999; Li 1999). It is easy to understand that since MMR proteins are
involved  in  such  a  large  number  of  cellular  mechanisms  contributing  to  DNA
integrity and apoptosis, the defects in MMR system are extremely harmful to
normal cell function.
5. Wnt pathway in cancer
The Wnt signaling pathway is very ancient, dating back to at least 650 million
years (Teo et al. 2006). The Wnt pathway is a key component controlling
patterning and organogenesis in the developing embryo by determining cell fate
and axis formation in all metazoan organisms (Willert and Jones 2006).
Overactivation of the Wnt pathway results in expression of specific target genes
leading  to  cell  growth  and  proliferation,  and  finally  to  carcinogenesis.  In  the
absence of an activating signal (see Figure 4), adenomatous polyposis coli (APC)
forms a degradation complex with axin and glycogen synthase kinase-3  (GSK3 )
which directs –catenin to ubiquitination and degradation (Orford et al. 1997).
When the Wnt pathway is activated by a Wnt ligand via the Frizzled receptor, or
by activating mutations, the degradation complex is destabilized and –catenin
can  enter  the  nucleus  where  it  operates  as  a  co-activator  of  transcription  factors
(Morin et al. 1997). Target genes, such as c-MYC (He et al. 1998), CD44 (Wielenga et
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al. 1999) and cyclin D1 (Tetsu and McCormick 1999), function mainly in
determining cell fate and proliferation, as well as promoting CIN.
Figure 4 Activation  and  key  components  of  the  Wnt  pathway.  In  the  absence  of
Wnts, -catenin is phosphorylated by GSK3  in multiprotein complex in
which  Axin  and  APC  are  also  included.  Wnt  signaling  leads  to
stabilization of -catenin  that  enters  the  nucleus  and  co-activates  target
gene transcription. APC, adenomatous polyposis coli; Cat, -catenin;
Dsh, dishevelled; GSK3 , glycogen synthase 3 ; TCF, T-cell factor; Wnt,
Wnt-ligand.
The variety of target genes activated by the Wnt pathway explains its important
role in the initiation of tumorigenesis. In the adenoma-carcinoma sequence of
colorectal carcinogenesis (Kinzler and Vogelstein 1996), loss of APC function is
one of the earliest events in the transformation, leading to formation of adenomas
(Jen et al. 1994). Mutations in APC are not sufficient for progression to carcinomas,
however, but provide a growth advantage by the activation of certain critical
target genes. Further mutations in tumor suppressor genes and in different
pathways are required (Vogelstein and Kinzler 1993; Vogelstein and Kinzler
2004). This can be accomplished by chromosomal instability, as is the case in most
CRCs.
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6. PI3K/AKT pathway in cancer
The phosphatidylinositol 3-kinase (PI3K)/AKT pathway is, in addition to the Wnt
pathway and MMR pathway, an important regulator of mammalian cell
proliferation  and  survival.  A  number  of  genes  such  as PIK3CA encoding p110
(Samuels et al. 2004), PTEN (Yokoyama et al. 2000), and AKT (Ringel et al. 2001) in
the PI3K/AKT pathway are dysregulated in a wide variety of human cancers.
PI3Ks constitute a large family of heterodimeric proteins with separate regulatory
(e.g. p85) and catalytic (e.g. p110) subunits. The PI3K family is divided into three
classes (I-III) differing in structure, substrate specificity, mechanism of activity,
and function (Vanhaesebroeck and Waterfield 1999; Wymann et  al. 2003). The
most important and best known class involved in tumorigenesis is the class IA
proteins, which consist of regulatory p85 and catalytic p110 (Domin and
Waterfield 1997; Walker et al. 1999). Figure 5 illustrates the key effects of the active
PI3K/AKT pathway. In the absence of an activating signal from the cell membrane
receptor tyrosine kinase, p85 binds to p110  and inactivates its kinase activity.
When a growth factor binds to a receptor tyrosine kinase, p85 docks to the
activated receptor, relieves the inhibition of p110 , and mediates the recruitment
of the catalytic subunit to the plasma membrane (Yu et al. 1998). Activated p110
phosphorylates phosphatidylinositol 4,5-biphosphate (PIP2) to become the tumor
promoting second messenger phosphatidylinositol 3,4,5-triphosphate (PIP3). PIP3
recruits proteins containing a pleckstrin homology domain such as AKT, PDK1,
and PDK2 to the cellular membrane (Osaki et al. 2004), where PDKs
phosphorylate AKT. Activated AKT is the predominant and essential mediator of
survival, growth, and proliferation stimuli leading to carcinogenesis acquired by
PI3K.
The catalytic subunit of PI3K is encoded by a PIK3CA gene (Samuels et al. 2005).
PIK3CA is mutated in 25-40% of sporadic cancers of the colon, rectum and
stomach (Samuels et  al. 2004), endometrium (Oda et al. 2005), and breast
(Campbell et al. 2004). PIK3CA acts  as  an  oncogene,  since  virtually  all  observed
mutations are missense mutations clustered in functionally important regions
(kinase and helical domains) that are highly conserved through evolution
(Samuels et al. 2004). Functional studies show that PIK3CA mutations increase the
activity of PI3K (Ikenoue et  al. 2005; Kang et al. 2005; Samuels et al. 2005). In
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addition, amplification of the PIK3CA gene associated with increased PI3K
activity occurs at least in ovarian cancer (Byun et al. 2003; Shayesteh et al. 1999).
Figure 5 PI3K/AKT  pathway  activation.  Binding  of  a  growth  factor  to  a  receptor
tyrosine kinase initiates the signaling leading to activation of AKT. AKT
regulates a great variety of target proteins by phosphorylation. Molecules
shown in green are prosurvival molecules that are activated by AKT and
molecules in red are proapoptotic molecules that are inhibited by AKT.
AKT, v-akt murine thymoma viral oncogene homolog; BAD, member of
the Bcl-2 protein family; CREB, cAMP response element binding protein;
FKHR,  forkhead;  GF,  growth  factor;  GSK3,  glycogen  synthase  kinase  3;
IKK,  inhibitory  B  kinase;  NF-  B,  nuclear  factor  B;  PDK,  pyruvate
dehydrogenase kinase; PI3K, phosphatidylinositol 3-kinase; PIP2,
phosphatidylinositol biphosphate; PIP3, phosphatidylinositol
biphosphate; PTEN, phosphatase and tensin homolog; Ras, rat sarcoma
viral oncogene homolog.
The tumor suppressor gene PTEN is an important PI3K/AKT pathway member
that negatively regulates PI3K signaling by dephosphorylating PIP3 to PIP2 (Li et
al. 1997; Maehama and Dixon 1998; Steck et al. 1997). Loss of PTEN function
strongly  correlates  with  the  activation  of  AKT  in  cancer  cells  (Sun et al. 1999).
Activation of the PI3K/AKT pathway may thus result from activating mutations
in PI3-kinase genes or inactivating mutations in the tumor suppressor gene PTEN.
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AIMS OF THE STUDY
This study was conducted to elucidate the genetic background of
familial/hereditary cancers of the colorectum and endometrium in MMR
proficient and deficient cases. Specific aims were:
1. To define the pathways leading to familial colorectal carcinomas by
evaluating the role of selected target genes of tumorigenesis and the role of
genomic instability (I, IV)
2. To define  the  genetic  basis  of  familial  site-specific  endometrial  carcinoma
through studies of germline and tumor alterations (II, IV)
3. To examine the nature and role of the “second hit” in HNPCC colorectal
versus endometrial tumorigenesis by studying the role of loss of




1. Patients and samples
This study was based on Finnish familial and hereditary colorectal and
endometrial tumors and corresponding normal samples. Colorectal tumors were
from well-characterized families from the Hereditary Colon Cancer Registry of
Finland. All families fulfilled either Amsterdam or Bethesda criteria for HNPCC
and had been included in mutation analyses based on clinical and family criteria.
The families were divided into two groups based on whether a germline mutation
in  a  MMR  gene  (MLH1, MSH2, MSH6, or PMS2) was present (n=48) or absent
(n=24) after thorough mutation screening (Holmberg et al. 1998; Huang et al. 2001;
Liu et al. 2001; Renkonen et al. 2003).
All HNPCC associated cancers of the endometrium (n=60) were derived from
well-characterized HNPCC families with MMR gene germline mutations as
described above for CRCs. Collection of familial site-specific ECs (defined by the
presence of EC in at least one first-degree relative of the index patient, n=30) was
based on a consecutive series of patients treated for EC at the Department of
Obstetrics and Gynecology, Helsinki University Central Hospital, in 1986 – 1997.
All patients were interviewed for the family history of cancer and the information
received was confirmed through the church registries and the Finnish Cancer
Registry. The genetic background of these families was completely unknown.
Sample cohort for studying second hits in MLH1 (III) consisted of 47 HNPCC
patients with 25 CRCs and 32 ECs. Each patient carried one of the three Finnish
founder mutations in MLH1: Mut1 (3.5 kb in-frame deletion of codons 578-632 of
exon 16 and flanking sequences), Mut2 (frameshift mutation g>a at 454-1 splice
acceptor of exon 6), or Mut3 (missense mutation T>G at 320, I107R, in exon 4).
Fresh frozen and/or paraffin derived specimens of tumor and corresponding
normal tissues were collected from pathology departments of different hospitals
in  Finland  and  used  for  immunohistochemical  analysis  and  DNA  extraction.
Areas with pure normal or high tumor percentages, with minimal intervening
stroma or inflammatory cells, were selected and verified histologically and
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subsequently dissected for DNA preparation. Tumor percentages ranged from
50% to 95%. In some cases blood was also available for genomic DNA extraction.
2. Mutation and gene amplification analyses
All mutation detection methods used were based on PCR amplification. PCR was
performed by a standard method (unless reported otherwise) with initial heating
at 94°C for 1 min, followed by an additional 35 cycles with 1 min denaturation at
94°C, 1 min annealing at primer specific temperature, and 2 min elongation at
72°C. Final extension was achieved by 3 min incubation at 72°C.
2.1 Single-strand conformational polymorphism analysis (I, IV)
Single-strand conformational polymorphism (SSCP) analysis was used to screen
hotspot mutations in exon 15 of BRAF,  exon  2  of KRAS,  exon  3  of CTNNB1 -
catenin),  and in  exons 1,  9  and 20  of PIK3CA. Samples were PCR amplified and
separated on polyacrylamide gels with 1 x MDE Gel Solution (Cambrex Bio
Science Rockland Inc.). SSCP gels were silver stained after the run. Changes
observed  in  SSCP  were  confirmed  by  direct  sequencing.  Primer  sequences  for
detecting the hotspot mutations are published as follows: BRAF in publication I,
KRAS in Deng et al. (2004), CTNNB1 in Kitaeva et al. (1997), and PIK3CA exon 9 in
Li et  al. (2005).  Exons 1 and 20 of PIK3CA were divided into two overlapping
fragments to improve PCR amplification and are listed in publication IV.
2.2 Direct sequencing (I-II, IV)
Genes showing alterations by SSCP in studies I and IV were sequenced for
possible mutations in BRAF, KRAS, CTNNB1 and PIK3CA genes. PCR reactions
were performed with conditions and primers as described above.
Immunohistochemistry was used to pinpoint affected MMR genes in study II and
the individual exons of MLH1, MSH2, and MSH6 were thereafter sequenced with
primers described in Chadwick et al. (2001). Additionally, screening for two
MSH6 mutations previously found in the Finnish population was performed with
primers for fragment “4k” (Wu et al. 1999), for 3052delCT (Huang et al. 2001), and
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with primers described in our publication II for E995X (Vahteristo et al. 2001).
Furthermore, the possible presence of a frameshift mutation affecting the MSH6-
C8 repeat was evaluated using primers described in Malkhosyan et al. (1996). The
PCR conditions were as previously described.
The Finnish founder mutation, Mut1 (a large genomic deletion, described in
Nystrom-Lahti et al. [1995]) was searched for by a direct test in a PCR assay using
two forward primers. One primer preceding and the other one located within the
deleted fragment were used together with a common reverse primer, as this
mutation is not identifiable by exon-specific sequencing.
2.3 Multiplex Ligation-dependent Probe Amplification (II-IV)
Multiplex ligation-dependent probe amplification (MLPA) was used to detect
large genomic deletions and amplifications in MLH1, MSH2, and MSH6 (II, III)
using SALSA P003 and SALSA P008 MLPA kits, and in PIK3CA (IV) using SALSA
Gain probe mix P173 MLPA kit (MRC Holland). HNPCC samples from our
collection  known  to  carry  large  genomic  deletions  in  MMR  genes  were  used  as
positive controls when studying the respective genes. Normal DNA specimens
derived from lymphocytes of healthy controls were included in every assay. The
probe mixture SALSA P003 contains probes for all MLH1 and MSH2 exons.  In
addition, seven control probes for other genes from different chromosomes are
included. The SALSA P008 probe mixture contains probes for all MSH6 exons and
a complete set of probes for PMS2.  This  kit  also  contains  two  probes  for MLH1
exon 1, one for MSH2 exon 1, and six for MLH3 and MSH3 exons. Additional
target genes for other probes are TACSTD1, MYH, and APC.  The  SALSA  Gain
probe mix P173 contains 43 probe pairs from 28 tumorigenesis related genes that
have  been  reported  to  have  a  higher  copy  number  in  some  tumors,  including
three probes for the PIK3CA gene; one for the p85 binding domain (exon 1), one
for the C2 domain (exon 6), and one for the kinase domain (exon 18).
MLPA method is based on the usage of specific probes consisting two parts that
anneal adjacent to each other on the same DNA strand. After hybridization to the
target site these two oligos are ligated to form one single probe (ligation is
possible  only  when  both  of  the  oligos  are  annealed)  that  can  be  PCR  amplified.
For each MLPA reaction 100-150 ng of paraffin-derived DNA was denatured and
41
subsequently hybridized with the MLPA probes. Ligase-65 enzyme was used to
ligate the annealed probe pairs. The ligation products were amplified by PCR
using a fluorescently labeled primer. The PCR products were separated by
capillary electrophoresis (on ABI 3730 Automatic DNA sequencer, Applied
Biosystems) and analyzed using Genemapper v3.0 or v4.0 (Applied Biosystems).
Relative peak values were calculated by dividing each peak area by the sum of all
peak areas of that sample. The resulting relative peak value was then divided by
the mean relative peak value of normal DNAs from healthy controls,  to obtain a
dosage ratio (formulas below).
where D is the dosage ratio, Px is the peak area of a given probe, Ptot is the sum of
all peak areas of all probes. T denotes tumor and N normal sample. For sequences
present in two copies/diploid genome, a dosage ratio of 1 is expected. Dosage
ratio of <0.6 was considered a deletion and > 1.7 an amplification.
2.4. Quantitative real-time PCR (IV)
Primers and Taqman probes were designed for PIK3CA exon 21 and glucokinase
gene  (GCK) exon 2 by using Assays-by-Design File Builder software (Applied
Biosystems). All primers and detailed PCR conditions are presented in
publication IV. All samples were subjected to PicoGreen (Invitrogen)
measurement prior to real-time PCR analysis to obtain equal DNA concentrations
in all samples. In each assay (96 wells), a no-template background control, and a
positive control were included. A normal colorectal tissue specimen was also
included as a calibrator sample. The PCR was performed in the ABI 7500
Sequence Detection System (Applied Biosystems). A validation experiment was
carried out according to guidelines “Real-time PCR Systems Chemistry Guide”
(Applied Biosystems). The practically identical slopes of the target gene and
reference gene demonstrated equal efficiencies of amplification over a range of
DNA concentrations, making it possible to calculate PIK3CA copy number using
the comparative threshold cycle (CT) method (Applied Biosystems).
D = (Px/Ptot)T / mean of (Px/Ptot)N
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3. Loss of heterozygosity analyses (I-III)
LOH  at  the MLH1 locus was studied by two quantitative methods, the Matrix
Assisted Laser Desorption Ionization – Time-of-Flight (MALDI-TOF) and Single
Nucleotide Primer Extension (SNuPE). LOH was also studied by analyzing a set
of microsatellite markers. For all different applications for LOH detection, the
ratio of allelic peak areas or frequencies was calculated as follows:
where L is the LOH ratio, A1T is the area of allele 1 in the tumor, A2T is the area of
allele 2 in the tumor. A1N is the area of allele 1 in the normal sample, and A2N is
the area of allele 2 in the normal sample. A sample was scored as showing LOH if
L  0.6 or L  1.67 (indicating that one of the alleles have decreased by 40% or
more), and was scored as showing putative LOH or allelic imbalance if 0.6 < L <
0.8 or 1.25 < L < 1.67 (indicating a decrease of 21-39% for one allele).
3.1 Matrix-Assisted Laser Desorption/Ionization – Time-of-Flight
(III)
MALDI-TOF was used to determine LOH at the MLH1 locus  using  two  single
nucleotide polymorphisms (SNP) (promoter G>A rs1800734 and exon 8 G>A
rs1799977) and two mutations (Mut2, g>a at 454-1 splice acceptor of exon 6, and
Mut3,  T>G  at  nucleotide  320  in  exon  4)  in  the MLH1 gene. The assays were
calibrated using DNA samples with known genotypes (determined by
sequencing). Based on titration experiments using the PicoGreen assay (Molecular
Probes),  samples  of  5  ng  of  DNA  isolated  from  normal  and  tumor  tissue  of  the
patients were then subjected to the MassEXTEND assay (Sequenom Inc.).
Amplification was performed with standard PCR conditions, primers are listed in
publication III. The PCR product was purified from uncorporated dNTP’s with
shrimp alkaline phosphatase (SAP) (GE Healthcare) by incubating the samples at
37°C for 20 min. The SAP enzyme was heat inactivated for 5 min at 85°C.
 After purification, the primer extension reaction was carried out with primers
that matched the target sequence adjacent to the studied SNP. Each reaction
L = (A1T/A2T) / (A1N/A2N)
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contained 0.58 units of Thermosequenase enzyme (GE healthcare) 1x termination
mix  (dNTPs/ddNTPs)  and  5  µM  of  test  specific  MASSEXTEND  primer
(Metabion). After the primer extension cycles, the products were treated with ion
exchange resin (Sequenom Inc.) to remove salts. Each reaction was then spotted to
a Maldimatrix-containing Advanced SpectroCHIPS (Sequenom Inc.) and
subjected to MALDI-TOF mass spectrometry. The SpectroCHIPS were analyzed
by an Autoflex MassARRAY mass spectrometer (Bruker Daltonics). All samples
were assayed at least in triplicate and two people performed the analysis
independently. The degree of LOH was calculated as previously described. An
example of a tumor sample showing LOH is illustrated in Figure 6.
Figure 6 Loss of MLH1 Mut3 (T>G at 320 in exon 4, MLH1e4-320) wild type allele.
Arrow denotes loss of T allele in the tumor sample. N, normal sample; T,
tumor sample of the same patient with CRC.
3.2 Single Nucleotide Primer Extension (III)
Single nucleotide primer extension (SNuPE) was used to verify the MALDI-TOF
method  of  LOH  detection,  by  analyzing  the MLH1 exon 8 polymorphism (G>A
rs1799977). SNuPE has previously been used in our laboratory to quantify the
relative expression of mRNA transcripts and the method is described in
Renkonen et al. (2003). Genomic DNA was PCR amplified and used as a template
for the primer extension reaction, where the primer extension continues until the
terminator ddATP is incorporated into alleles having A at the polymorphic site.
For alleles with a G at the polymorphic site the strand elongation continues until
the next A is reached and ddATP is incorporated into the elongated fragment. The












(on ABI 3730 Automatic DNA sequencer, Applied Biosystems) and analyzed
using Genemapper v4.0 (Applied Biosystems). Allelic dosages were determined
from the peak areas of the fragments and their ratios in the tumor DNA relative to
normal DNA were calculated as previously described.
3.3 Analysis of microsatellite markers to detect LOH (I-III)
Loss of heterozygosity can also be analyzed by studying microsatellite markers.
We used microsatellite markers inside and around MLH1 (D3S1612, D3S3512,
D3S3718, D3S1611, D3S1298, and D3S3521) to study the width of LOH in study
III. In studies I and II we used the Bethesda panel of five markers (BAT25, BAT26,
D5S346, D2S123, and D17S250) to study LOH. In study II additional markers
flanking MLH1 (BAT21, D3S1611, and D3S1298), and MSH2 and MSH6 (D2S2378
and CA7) were used, and in study I another nine markers (D1S244, D1S228,
D1S2667, D4S2962, D8S507, D9S167, D10S219, D13S263, and D18S474) were
studied  for  LOH.  Primers  and  PCR  conditions  for  microsatellite  markers  are
available at The GDB Human Genome Database (http://gdbwww.gdb.org/) and
for BAT21, BAT25, and BAT26 at Alvino et al. (2002). As the forward primers were
fluorescently  labeled  the  PCR  products  were  run  on  an  automated  DNA
genotyper (ABI3730, Applied Biosystems) and the data was analyzed with the
Genotyper 2.0 or with GeneMapper v3 software (Applied Biosystems).
Calculations for LOH status were done as previously described.
4. Instability analyses
4.1 Detection of microsatellite instability (I-III)
Tumor samples were screened for MSI using the Bethesda panel of five
microsatellite markers (BAT25, BAT26, D2S123, D5S346 and D17S250) as
recommended by the International Workshop (Boland et  al. 1998). All markers
were run on an ABI3730 genotyper (Applied Biosystems) and analyzed by the
Genotyper 2.0 or GeneMapper v3 software (Applied Biosystems).
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4.2 Detection of chromosomal instability (I)
Comparative genomic hybridization (CGH) was used to detect chromosomal
instability. Chromosomal CGH was performed according to a previously
described method (el-Rifai et al. 1997) using a mixture of fluorescein-iso-
thiocyanate (FITC)-conjugated dCTP and dUTP (Dupont) in tumor DNA labeling
by nick translation. Reference DNA was conjugated with Texas Red (Dupont) and
labeled as described for tumor DNA. The use of a fluorochrome-dCTP and -dUTP
mixture in labeling produces fewer artifacts, yields higher quality results, and
more representative labeling of the genome (el-Rifai et al. 1997). The results were
analyzed by ISIS digital image analysis system (MetaSystems GmbH) with an
integrated high-sensitivity monochrome charge-coupled device camera and
automated CGH analysis software.
5. Methylation analyses
5.1 HpaII/MspI assay (II)
The MLH1 promoter methylation status was analyzed by HpaII/MspI assay. This
relies on the inability of HpaII to cut methylated CCGG sequences. Four HpaII
target sites occur in the MLH1 promoter region (-567, -527, -347, and -341)
(Kuismanen et  al. 1999). We investigated them in three separate reactions. Each
sample was analyzed in three settings: (1) the sample was digested by HpaII to
reveal methylation in the case the internal cytosine at the target site was
methylated, (2) the sample was digested with MspI, which is insensitive to
methylation but shares the digestion site with HpaII, to verify the presence of the
target site, (3) undigested DNA was used as a positive control in the PCR. These
three parallel analyses were then PCR amplified and ran on an agarose gel to
detect for methylation. If the studied CCGG sequence was methylated a band was
present in the HpaII treated sample and in the undigested sample while no band
was present in the MspI treated sample. Detailed protocols and PCR primers are
described in Kuismanen et al. (1999).
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5.2 Methylation specific MLPA (III)
Methylation of the MLH1 promoter was studied as a second hit by a methylation
specific  (MS)  -MLPA  method  using  the  SALSA  MS-MLPA  ME001  kit  (MRC
Holland). The kit contains probe pairs for 24 tumor suppressor genes including
two probes for the MLH1 gene and 15 control probes lacking the HhaI site. The
MS-MLPA method relies on the inability of the HhaI restriction enzyme to digest
methylated  target  sequences,  producing  a  signal  for  methylation  after  PCR
amplification. If the target site is unmethylated, the genomic DNA/MS-MLPA
probe complex will be digested, which prevents PCR amplification, and no signal
will be generated. All reactions were carried out according to the manufacturer’s
instructions. Normal DNA specimens derived from the lymphocytes of healthy
controls were included in every assay. For each MLPA reaction 100 ng of paraffin-
derived DNA was denatured and subsequently hybridized with the MLPA
probes. After hybridization, the hybrids were divided into two halves, one for
ligation reaction and the other one for both ligation and digestion reactions.
Ligase-65 enzyme was used to ligate the annealed probe pairs and HhaI
restriction enzyme was used to digest (unmethylated) ligation products. The rest
of the analysis was done as previously described in section 2.3. Figure 7 illustrates
a tumor sample showing methylation at MLH1 locus. Dosage ratio was obtained
by a following calculation:
where Dm is the methylation dosage ratio, Px is the peak area of a given probe, Pctrl
is the sum of all peak areas of control probes. Dig denotes HhaI digested sample
and Undig undigested sample. Based on our titration experiments with cell lines
known to have full methylation (RKO) or a complete lack of methylation of MLH1
(HCT116), as well as on studies in which we correlated the methylation level and
MLH1 protein expression by immunohistochemical analysis, a dosage ratio of
0.10 or higher at the CpG island adjacent to the translation start site of MLH1
(corresponding to 10% of methylated DNA) was regarded to indicate promoter
methylation.
Dm = (Px/Pctrl)Dig / (Px/Pctrl)Undig
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Figure 7 Methylation of MLH1 promoter detected by MS-MLPA. The
chromatogram  shows  altogether  41  peaks  of  which,  26  peaks  denote
methylation sites in 24 tumor suppressor genes and an additional 15
peaks control genes. Control genes always produce a peak after PCR and
target genes only when methylated. I, undigested normal sample; II HhaI
digested normal sample; III, undigested tumor sample; IV, HhaI
digested  tumor  sample  showing  methylation  at MLH1 promoter and







6. Protein expression analysis
6.1 Immunohistochemical analysis (I, II, IV)
Protein expression was studied using immunohistochemistry on 3-5µm thick
formalin-fixed paraffin-embedded tissue sections mounted on silanized slides
(Dako). Most of the slides included tumor and corresponding normal tissues from
the same section. The normal tissue was used as an internal reference for the
evaluation of the staining results. Dewaxing and rehydration was performed with
xylene and EtOH series. The antigen-retrieval step was performed by microwave
boiling as shown in Table 5. After cooling the slides were washed in Tris-buffered
saline, pH 7.2, and the subsequent steps were performed using the EnVision+
System-HRP (DAB) (Dako) according to manufacturer’s instructions. In addition,
prior  to  primary  antibody  incubation,  the  slides  were  incubated  with  10%
nonimmune goat serum (Dako) for 30 min. The mouse primary antibodies are
presented in Table 5. Nonimmune mouse IgG1 (Dako) was used as a negative
control for mouse primary antibodies. Finally, Mayer’s Hematoxylin was used for
counterstaining.
Table 5. Antibodies and antigen retrieval step used in immunohistochemistry
Protein Primary antibody Buffer Microwave treatment
MLH1 anti-MLH1 clone G168-15;
Pharmingen
EDTA buffer, pH 8.0 10 min at 750W
MSH2 anti-MSH2 clone FE-11;
Calbiochem/Oncogene Research
EDTA buffer, pH 8.0 10 min at 750W
MSH6 anti-MSH6 clone 44; Transduction
Laboratories
EDTA buffer, pH 8.0 10 min at 750W
PTEN anti-PTEN clone 6H2.1; Cascade
Biosciences
10mM citrate buffer pH 6.0 20 min at 750W
-catenin anti- -catenin clone 14; BD
Transduction Laboratories
10mM citrate buffer pH 6.0 5 min at 750W followed by
5 min at 450W
CDX2 anti-CDX2 clone CDX2-88;
BioGenex
10mM citrate buffer pH 6.0 5 min at 750W followed by
5 min at 450W
p53 anti-p53 clone DO7;
DakoCytomation
10mM citrate buffer pH 6.0 5 min at 750W followed by
5 min at 450W
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7. Statistical analyses
Statistical  significance  for  differences  between study groups was evaluated with
the  Fisher’s  exact  test,  2, or t-test (VassarStats at
http://faculty.vassar.edu/lowry/VassarStats.html), as appropriate. All reported p-




1. Molecular classification of familial CRC (I, IV)
This study was based on our previous observation that 58% of HNPCC families
that  meet  the  diagnostic  criteria  for  HNPCC  but  lack  MMR  gene  germline
mutation (Holmberg et al. 1998; Huang et al. 2001; Liu et al. 2001; Nystrom-Lahti et
al. 1996) still remain MMR gene mutation negative after comprehensive mutation
screening by advanced methods (Renkonen et al. 2003). We studied the molecular
background of HNPCC mutation positive and negative CRCs to find out if
molecular differences exist between these two groups.
1.1 HNPCC mutation positive CRC
All  48  HNPCC  colorectal  tumors  with  predisposing  MMR  gene  germline
mutations showed loss of the respective protein by immunohistochemistry and
most of the tumors had MSI-high phenotype (one MSI-low, one MSS). The Wnt
signaling pathway was studied in 31 tumors and it was deregulated due to
aberrant -catenin in 25/31 (81%) (Kariola et al. 2005), of which 9/25 (36%) had an
activating mutation in CTNNB1 exon 3. Immunohistochemical studies on CDX2
revealed complete or partial expression loss in 2/31 (6%) tumors, while normal
colonic epithelia showed strong nuclear staining. We found no mutations in
CDX2. Stabilization of the p53 protein was observed with immunohistochemistry
in only 4/31 (13%) tumors and it was found to be due to a pathogenic mutation in
TP53. The RAS and PI3K/AKT pathways were studied in all 48 HNPCC
associated CRCs. RAS pathway members KRAS and BRAF were sequenced for
mutations in known hot spots. Altogether 15/48 (31%) tumors showed KRAS
mutations that were distributed equally in codons 12 and 13. We found no BRAF
mutations. The PI3K/AKT pathway was altered in 27/48 (56%) tumors. The key
regulator of the PI3K/AKT pathway, PIK3CA, showed alterations in 8/48 (17%)
tumors,  of  which  five  were  mutations  and  four  amplifications  (one  tumor  had
both alterations). In the same tumors PTEN, the counter-effector for PIK3CA,
showed decreased or lost expression in 16/44 (36%). PIK3CA and PTEN alterations
occurred simultaneously in three tumors.
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1.2 HNPCC mutation negative CRC
All  but  two  of  the  24  colorectal  tumors  negative  for  MMR  gene  germline
mutations were MSS and showed normal expression of MLH1, MSH2, and MSH6
by immunohistochemistry. Two tumors had unstable microsatellites and absent
or weak MLH1 expression possibly due to detected MLH1 promoter methylation.
All immunohistochemical studies could be performed on 18 tumors, based on
availability of tissue sections. Abnormal Wnt signaling was present in 7/18 (39%)
tumors indicated by nuclear -catenin, but in contrast to mutation positive
HNPCC  CRCs,  no CTNNB1 mutations were identified. Meanwhile, in 6/7 (86%)
tumors the nuclear -catenin was coupled with the lost APC expression.
Furthermore, four of these tumors showed chromosomal loss of the APC locus by
CGH or LOH analysis. Tumor specific CDX2 expression changes were observed
in 2/18 (11%) MMR mutation negative tumors and none of the tumors had
mutations in CDX2 exon 3. Altogether 8/18 (44%) MMR gene mutation negative
tumors showed p53 stabilization and among those, pathogenic mutations were
identified in 5/8 (63%). Sequencing of KRAS and BRAF revealed mutations in both
genes, although only one tumor harbored BRAF V600E mutation. All four KRAS
mutations affected codon 12, in contrast with tumors harboring MMR gene
mutations. The PI3K/AKT pathway was altered in 13/22 (59%) tumors. Only two
tumors (10%) showed PIK3CA alterations, of which one was a mutation and the
other one an amplification. PTEN, the repressor of PI3K/AKT pathway, was
altered in 8/18 (44%) tumors. None of the tumors showed concomitant PIK3CA
and PTEN alterations.
We observed certain molecular distinctions between MMR gene mutation positive
and mutation negative CRCs. First, Wnt pathway was affected by an abnormal -
catenin far more frequently in MMR mutation positive tumors than mutation
negative tumors (81% vs. 36%, p=0.005). Second, the frequency of p53 stabilization
was significantly higher in the MMR gene mutation negative tumors compared to
mutation positive tumors (p=0.04).
MMR gene mutation negative tumors could be further divided into two groups,
according to CGH results. A chromosomally stable group (CIN-) consisted of 9/16
(56%)  of  all  tumors  studied  and  they  all  showed  less  than  five  (mean  1)
chromosome arm gains or losses. The rest of the tumors were classified as the
unstable group (CIN+) with chromosome arm gains or losses ranging from 7 to 18
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(mean 10.6). The biggest molecular differences between CIN- and CIN+ groups
were localization of -catenin, in the frequency of altered PI3K/AKT pathway and
LOH. Membranous -catenin and alterations in PI3K/AKT pathway were
associated with CIN- carcinomas (6/7 in CIN- group vs. 0/6 in CIN+ group,
p=0.005), and LOH with CIN+ carcinomas (Table 6).
Table 6. Colorectal tumors classified according to MMR defect and CIN
MMR gene mutation positive
CRC
MMR gene mutation negative
CRC*
Genetic instability MSI (n=48) MSS/CIN- (n=9) MSS/CIN+ (n=7)
Mean age at onset 45.2 53.7 58.6
Main location  of CRC right-sided right-sided left-sided
Localization of -catenin nuclear membranous nuclear
TP53 mutations frequent infrequent frequent
LOH frequency** ND 36% 48%
Altered PI3K/AKT pathway† 27/48 (56%) 5/7 (71%) 3/9 (33%)
Altered RAS pathway‡ 15/48 (31%) 0/7 (0%) 2/9 (22%)
ND, not determined; *Including only CRCs with known CIN status; **Average degree of LOH per
tumor when 11 markers were studied; †Mutation or amplification of PIK3CA and  altered  PTEN
protein expression are included; ‡ Mutation in BRAF and KRAS are included.
2. Molecular classification of familial EC (II, IV)
Familial clustering of endometrial cancer may occur as a part of HNPCC with
MMR gene germline mutations, or it may constitute a separate entity termed
familial site-specific endometrial carcinoma. The criteria we used for the familial
site-specific EC was that the EC needed to be present in at least one first-degree
relative of the index patient and any associated clustering of other cancers non
existent. We have molecularly characterized both HNPCC associated and non-
associated ECs to clarify the genetic basis of familial endometrial cancers.
2.1 EC as a part of HNPCC tumor spectrum
MMR gene germline mutations were found in 11/519 (2%) consecutive EC
patients diagnosed at the Department of Obstetrics and Gynecology, Helsinki
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University Central Hospital in ten years time. Nine of these patients belonged to
families with CRC and could therefore be diagnosed with HNPCC at the outset.
Six of the patients with HNPCC associated EC carried germline mutation in
MLH1 and three  in MSH2.  Two additional  EC patients,  both from families  with
clustering of EC only, showed germline mutations in MMR genes. A truncating
germline mutation in MSH6 (3261insC) was identified in one family and a
missense  mutation  in MSH2 (D603N) was identified in another. Both of the
families displayed clustering of EC only without any other cancers. Our findings
demonstrate that EC may be the only manifestation of HNPCC, although HNPCC
families presenting with EC only merely constitute a small fraction of families
with site-specific EC.
These 11 ECs, with MMR gene germline mutations, were included into our
existing HNPCC EC panel to make a total of 60. All showed loss of the respective
protein by immunohistochemistry. In contrast to studied HNPCC associated
CRCs in which all but two were MSI, 22/60 (37%) of the HNPCC associated ECs
demonstrated MSS.
We  studied  the  role  of  the  PI3K/AKT  pathway  in  EC  as  well  as  in  CRC
tumorigenesis. PIK3CA was altered in 10/60 (17%) of HNPCC associated ECs and
37/53 (70%) showed PTEN expression changes. Most (7/10, 70%) of the PIK3CA
alterations  were  mutations  in  this  group  of  ECs. KRAS was relatively seldom
affected since only 6/60 (10%) of tumors showed KRAS mutation.
2.2 Familial site-specific EC
Most (20/22, 91%) of the families with familial site-specific EC could not be shown
to be associated with MMR gene germline mutations. Still, immunohistochemical
analyses of 29 available tumors revealed that the expression of MLH1 was lost in
seven  tumors,  MSH2  coupled  with  MSH6  in  two  tumors,  and  MSH6  alone  in
three tumors. MSI status was determined for all 30 ECs and 4/30 (13%) displayed
MSI-high, 5/30 (17%) MSI-low, and 21/30 (70%) MSS phenotype. Only 4/30 (13 %)
of ECs displayed MSI-high and showed lost MMR protein expression. All five
tumors with loss of MSH2 and/or MSH6 expression showed LOH or putative
LOH at one of the flanking markers. Only 2/7 ECs with lost MLH1 expression
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displayed LOH at the intragenic D3S1611 marker and 1/7 tumors showed MLH1
promoter methylation.
The MMR gene mutation negative ECs showed PIK3CA alterations in 9/30 (30%)
tumors. PIK3CA amplifications were the predominant alteration observed in
PIK3CA among these ECs, occurring more frequently when compared to HNPCC
associated ECs (7/29 vs. 3/57, p=0.015). Moreover, the degree of amplification was
higher  in  the  former  vs.  latter  group  of  ECs  (average  copy  number  ratio  5.0  vs.
3.5). PTEN was expressed in an abnormal manner in half (14/28, 50%) of the
studied tumors, and as in HNPCC associated ECs, KRAS was mutated in only
3/29 (10%) tumors.
Comparisons between HNPCC associated ECs and familial site-specific ECs are
shown in Table 7. These two study groups can not be easily discriminated by any
other alterations than MMR defects and PIK3CA amplifications.





Mean age at onset 50 63
MMR gene germline  mutation present absent
Altered MMR expression 60/60 (100%) 12/29 (41%)
Tumors with MSI 38/60 (63%) 4/30 (13%)
Alterations in PIK3CA 10*/60 (17%) 9**/30 (30%)
Alterations in PTEN 37/53 (70%) 14/28 (50%)
Alterations in KRAS 6/60 (10%) 3/29 (10%)
* 7 mutations, 3 amplifications; ** 2 mutations, 7 amplifications
3. Second hits in HNPCC associated CRC and EC (III)
To address the question of why different organs are differently susceptible
to cancer, although equally predisposed, we studied the mechanism of wild
type allele inactivation in 25 HNPCC associated CRCs and 32 HNPCC
associated ECs from 37 families. The study cohort represented a larger
series of carriers of the Finnish founder mutations in MLH1 (Mut1, Mut2
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and Mut3; Table 8). Haplotype conservation associated with each ancestral
founder mutation, as well as the nucleotide substitutions defining Mut2 and
Mut3 per se,  allowed us  to  determine if  LOH affected the  wild type or  the
mutant allele in each case. The clinical features of individual MLH1 founder
mutations were different (Table 8).
Table 8. Clinical features of a larger cohort of affected individuals with Mut1,
Mut2,  or  Mut3  (331  individuals)  from  which  the  study  cohort
(47 individuals) was assembled
MLH1 Mut1 MLH1 Mut2 MLH1 Mut3 Total (Mut1-3)
Total no of individuals 247 63 21 331
with CRC 226 51 19 296
with EC 57 20 7 84
Average age at diagnosis of
first cancer 44.7 47.1 47.2 45.3
any CRC 45.2 49.0 50.7 46.3
any EC 51.3 46.3 48.9 49.9
CRC to EC ratio 4.4 3.0 3.4 4.0
Proximal to distal ratio (CRC) 1.4 1.6 1.8 1.5
Mut1, 3.5kb genomic deletion affecting codons 578-632 of exon 16 and flanking intron
sequences; Mut2, g>a at 454-1 splice acceptor of exon 6; Mut3, T>G at 320 in exon 4, I107R.
Loss of heterozygosity was present in 31/57 (54%) of all studied HNPCC tumors,
and the wild type allele was deleted more often than the mutant allele (23/57 for
wild type allele vs. 8/57 for mutant allele, p=0.003). MLH1 promoter methylation
occurred in 4/55 (7%) tumors, and the tumors with MLH1 methylation also
showed  significantly  more  methylation  in  other  tumor  suppressor  genes
compared to those without MLH1 methylation (average of 10/23 methylated loci
vs. average of 2/23 methylated loci, p<0.0001).
Among CRCs with a predisposing mutation in MLH1, LOH affected 16/25 (64%)
tumors. When different predisposing mutations were analyzed separately, LOH
was present in all but one of the tumors among Mut1 carriers (10/11, 91%), but it
was absent in 5/10 (50%) and 3/4 (75%) of the CRCs with Mut2 and Mut3. MLH1
promoter methylation occurred in 4/23 (17%) CRCs. MLH1 methylation was
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absent from tumors with wild type allele LOH and only affected tumors without
LOH or with mutant allele LOH (0/14 vs. 4/10, p=0.02). One CRC with both LOH
and methylation had lost the mutant allele suggesting that methylation affected
the wild type allele.
The presence  of  LOH in ECs was opposite  to  CRCs.  Most  of  the  observed LOH
affected Mut3 and Mut2 carriers (4/5, 80% and 10/14, 71%), whereas LOH among
Mut1 ECs was a rare event (1/13, 8%; 14/19 for Mut2 and Mut3 together vs. 1/13
for Mut1, p=0.0003). Furthermore, Mut2 and Mut3 ECs had lost their mutant allele
relatively more frequently compared to Mut1 ECs. The total frequency of LOH
observed in ECs was 15/32 (47%) and none of the ECs showed MLH1 promoter
methylation.
The major differences in second hits between HNPCC associated CRCs and ECs
were as follows. The wild type allele LOH predominated in CRC irrespective of
the predisposing MLH1 mutation whereas wild type and mutant allele LOH were
roughly equally common in EC. Among CRCs, the LOH status of MLH1 did not
correlate  with  the  age  at  onset,  however,  ECs  with  wild  type  allele  LOH  were
diagnosed at a significantly earlier age (mean 43.2 years) compared to ECs with
no LOH (mean 53.6 years; p=0.003). For Mut1, LOH was significantly more
frequent in CRC than EC (10/11 for CRC vs. 1/13 for EC, p>0.0001) whereas for
Mut2  and  Mut3  LOH  was  slightly  more  common  in  EC.  Although MLH1
promoter methylation rarely occurred, all four tumors displaying MLH1
methylation were CRCs.  The average number of methylated loci among Mut2
and Mut3 carriers was higher in CRC than EC (5.8 vs. 2.6, p=0.017) that is opposite
to the observed LOH frequencies among the same tumors.
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DISCUSSION
1. Molecular classification of familial CRC
The  most  common  hereditary  form  of  CRC  is  HNPCC,  but  up  to  half  of  the
families meeting the diagnostic criteria for HNPCC fail to show any germline
mutations in DNA MMR genes (Abdel-Rahman et al. 2006). HNPCC tumors with
MMR  defects  represent  the  MSI  pathway  in  tumorigenesis  and  are  virtually  all
lacking gross chromosomal gains and losses (Aaltonen et  al. 1993). On the
contrary, sporadic MMR proficient (MSS) tumors show chromosomal instability
as a major feature (Abdel-Rahman et  al. 2001; Lengauer et  al. 1997). It has been
considered that these two instability pathways, MSI and CIN, are independent
(Abdel-Rahman et al. 2001; Lengauer et al. 1997). Which pathways then lead to the
HNPCC phenotype without a MMR defect?
We studied the role of five pathways (MMR, Wnt, p53, CIN, and PI3K/AKT) in
MMR mutation positive and negative HNPCC tumors. While the Wnt pathway is
reported to be active in the majority of CRCs, regardless of the MSI status (Huang
et al. 1996; Morin et al. 1997; Rowan et al. 2000; Sparks et al. 1998), the MMR
mutation negative tumors studied here showed inactivity of the Wnt signal
pathway in a majority of tumors. The same tumors were also distinguished by the
absence  of  chromosomal  instability  (CIN-)  and TP53 mutations. Moreover, TP53
mutations were absent even in tumors with p53 stabilization, shown by
immunohistochemistry, in this “stable” subset. These findings were significantly
different from those observed in CRCs from (1) the MMR gene mutation positive
families where the Wnt signaling pathway was activated in 81% of the tumors
and p53 stabilization was due to TP53 mutation in all cases and from (2) sporadic
CRCs where the majority of tumors show an active Wnt pathway (Hao et al. 2002;
Iwamoto et al. 2000) mutated TP53 (Konishi et al. 1996; Leslie et al. 2003; Salahshor
et al. 1999), and chromosomal instability (CIN+)(Leslie et  al. 2003; Schlegel et  al.
1995). Such a high occurrence (9/17, 56%) of stable carcinomas with no apparent
changes  in  the  four  major  pathways  (MMR,  Wnt,  p53,  and  CIN)  is  unique.  The
only comparable report we could find showed only an occurrence of 3/50 (6%)
(Leslie et al. 2003), the difference being highly significant (p=0.00008).
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Parsons et al. (2005) found that nearly 40% of sporadic colorectal tumors had
alterations in one of eight PI3K pathway genes. The role of the PI3K/AKT
pathway in our MMR gene mutation positive and negative tumors was
significant. Although we focused on only three of these genes, PIK3CA, PTEN,
and KRAS, more than half of the tumors showed alterations. Our observation of a
mutually exclusive relationship between PIK3CA mutations and amplifications in
familial CRCs is consistent with studies on sporadic CRCs. Of PIK3CA alterations,
amplifications  and  mutations  were  equally  common  in  both  of  our  CRC  study
groups. This finding is in contrast to published reports for sporadic cancers
(Samuels et  al. 2004; Velho et  al. 2005) in which amplifications are rare or
completely absent, providing a possible distinguishing feature between the
familial tumors and their sporadic counterparts.
Our studies suggest that MMR gene mutation negative HNPCC families are not a
single  separate  entity,  but  they  can  be  divided  into  at  least  two  distinct  groups
according to chromosomal stability, -catenin localization, and TP53 mutation
frequency.  In  addition,  the  group  forming  a  majority  of  the  MMR  mutation
negative tumors (MSS/CIN-), have a tendency to affect the right colon and are
diagnosed at earlier age.
Collectively, at least the MMR, Wnt, p53, PI3K/AKT, and CIN pathways are not
the main ones giving rise to the MMR proficient HNPCC phenotype. Linkage
studies (Huang et al. 2001; Lewis et al. 1996) suggest that there might be novel loci
that could account for the unexplained fraction of HNPCC families with no
detectable  MMR  gene  mutations.  Part  of  such  families  may  be  due  to  shared
environment that has been shown to account for approximately 8% of familial
cases (Lichtenstein et al. 2000). Interactions between genes and environment are
also shown to be very important in cancer predisposition (Potter 1999). There are
also studies on rare variants or low-penetrance alleles that are seen in increased
frequencies in families with clustered CRC compared to control population. One
example is TGFBR1*6A variant. Although it is associated with a modest risk of
CRC in Caucasians (de la Chapelle 2004) it is more prevalent in patients meeting
Amsterdam criteria but lacking MMR gene mutation than in MMR gene mutation
positive HNPCC patients (Bian et al. 2005). Some of the rare variants may not
predispose to CRC when occurring alone, giving an explanation why they also are
seen in healthy controls to some extent. When these rare variants aggregate they
may  have  an  important  role  in  cancer  susceptibility.  Although  our  findings
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provide new insights into the mechanisms of colorectal carcinogenesis, the nature
of  the  predisposing  gene(s)  still  remains  unknown  and  further  studies  in  larger
series of CRC families are needed.
After our data was published (I), Johnson et al. (2005) published a study in which
they did not find similar molecular associations as we reported. Nuclear -catenin
expression  did  not  correlate  with  MMR  gene  mutations  or  with  p53  expression.
Their group of familial CRCs without molecular diagnosis of HNPCC was more
heterogeneous and larger than our MMR gene germline mutation negative CRC
group. Thus, the molecular definition and size of the study groups were different
between Johnson et al. (2005) and us, which may account for the differences
between these studies.
2. Molecular classification of familial EC
The genetic background of EC has not been studied as extensively as that of CRC.
A few studies reporting two different genetic models that may play a role in the
development of familial EC exist (Boltenberg et  al. 1990; Gruber and Thompson
1996; Sandles et al. 1992).  According to  these  models  familial  EC can be  divided
into two classes: one representing the HNPCC syndrome, which is associated
with germline mutations in MMR genes and the other representing familial site-
specific endometrial carcinoma, which genetic background is completely
uncharacterized. We studied the role of MMR genes as the first step in the
molecular dissection of familial site-specific EC.
In the study of 22 families with EC clustering only, around half (12/22) showed a
hint  of  a  MMR  defect  based  on  the  lack  of  MMR  expression  by
immunohistochemistry. In ten families, however, no germline mutation could be
found by sequencing, direct mutation testing (for mutations common in the
Finnish  population  not  detectable  by  direct  sequencing),  or  by  MLPA  (for  large
genomic deletions). In addition, 8/12 (67%) of the ECs from these ten families
displayed stable microsatellites (MSS or MSI-low) despite showing altered MMR
gene expression by immunohistochemistry. When analyzing the families more
closely, we found that in four families the immunohistochemical changes were
discrepant arguing against inherited MMR defect. The analyses of the remaining
six families with expression changes were based on one individual only. Thus no
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firm conclusions could be made, although we could speculate that these families
are  very  unlikely  to  be  associated  with  HNPCC  since  no  mutations  were  found
and only one of the tumors showed MSI. All five tumors with lost MSH2 and/or
MSH6 and 2/7 tumors with loss of MLH1 expression showed LOH at the nearest
markers. Altogether five of the tumors with lost MLH1 expression were later
shown to be hypermethylated at the MLH1 promoter (unpublished data),
probably suppressing the gene expression, shown in immunohistochemistry.
Altogether 2/12 families with MMR expression changes were found to carry a
predisposing germline mutation in the respective genes, MSH2 in Family 13 and
MSH6 in Family 15. These two families represent 9% of all 22 families studied,
selected by the presence of EC in at least one first-degree relative of the index
patient (in the absence of other cancers). Thus, the majority of families with site-
specific EC may be due to hereditary defects in other genes, nongenetic factors, or
chance.
Our  study  may  give  an  underestimation  of  MMR  mutations  in  the  above
mentioned families, since all tumors were not tested for mutations, but
immunohistochemistry was used to guide mutation analyses.  Based on our own
studies and the experience of others (Berends et al. 2001; Berends et  al. 2003; de
Leeuw et al. 2000; Schweizer et al. 2001), however, germline mutations constantly
lead to abnormal expression of the respective protein which can be observed with
immunohistochemistry. In contrast to what is observed in CRC, the correlation
between MMR gene expression and MSI was incomplete, since only one third
(4/12, 33%) of the studied ECs with observed MMR protein loss showed MSI. This
could  be  explained  possibly  by  the  earlier  detection  of  EC  compared  to  CRC,
when the MSI pattern may not be well developed and by the observation that
MMR  deficient  ECs  have  a  lower  mutational  rate  than  MMR  deficient  CRCs
(Duval et al. 2002). The panel of microsatellite markers used here and
recommended by the National Cancer Institute may not be optimal for ECs, since
the  panel  was  originally  developed  for  CRCs.  Therefore  MSI  detected  by  the
Bethesda panel markers might not be a definite indicator of a MMR defect in ECs.
Other reasons for the incomplete correlation by MMR protein expression and MSI
may include normal tissue contamination and clonal heterogeneity.
We studied HNPCC associated EC and familial site-specific EC for alterations in
the PI3K/AKT pathway members PIK3CA and  PTEN,  and  in KRAS that may
modulate the pathway. The pathway was affected in comparable proportions in
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both EC groups studied (43/60 [72%] for HNPCC associated ECs vs. 20/30 [67%]
for familial site-specific ECs) and the mutation frequencies were analogous to that
reported for sporadic ECs (Hayes et  al. 2006; Muller et  al. 2007; Oda et  al. 2005;
Velasco et al. 2006). In contrast, amplifications were characteristic of familial site-
specific  ECs  without  a  MMR  gene  germline  mutation,  being  more  frequent  in
such ECs compared to HNPCC associated ECs (7/24 vs. 3/57, p=0.015). Moreover,
when a recent publication on sporadic ECs showed amplifications in 1/9 (11%)
tumors with poor differentiation (Oda et  al. 2005), the amplifications that we
observed occurred in well differentiated and local ECs with endometrioid
histology – features that generally correlate with a better prognosis.  Notably, all
but one of the tumors with high-level (more than 4-fold) amplification were MSS,
supporting the idea of amplifications being a manifestation of CIN rather than a
manifestation of MSI (Lengauer et al. 1998).
Apart from the differences in the MMR defect and PIK3CA amplifications
HNPCC associated ECs and familial site-specific ECs seem broadly comparable
regarding their molecular characteristics. This is not surprising since the tumors
from these two groups show also minor clinical diversity. In addition, very slight
differences are found even when HNPCC associated ECs are compared to
sporadic ECs (Rijcken et al. 2006).
The existence of familial site-specific EC as a separate entity still remains
equivocal,  until  the  predisposing  gene  (or  genes)  is  found.  It  is  possible  that
familial site-specific EC is not due to one highly penetrant susceptibility gene,
however, but it might result from inherited polymorphic alleles that may act
alone or in different combinations. Further studies are clearly needed for the full
molecular characterization of this proposed EC entity.
3. Second hits and selective organ susceptibility in HNPCC
Selective organ susceptibility in HNPCC is poorly understood. MMR genes are
ubiquitously  expressed  and  their  function  in  DNA  repair  is  important  in  all
tissues. Still mutations in MMR genes lead to a selective development of tumors
in  particular  tissues.  In  HNPCC  a  wide  spectrum  of  cancers  is  found.  The
diagnostic criteria for HNPCC only list certain tumors (colorectal, endometrial,
small bowel, ureter, and renal pelvis) to be a part of the HNPCC tumor spectrum.
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Gastric,  ovarian,  hepatobiliary  tract,  and  brain  tumors  also  occur  in  excess  in
HNPCC (Aarnio et  al. 1999; Sijmons et al. 1998; Vasen et al. 1996; Watson and
Lynch 1993). In addition, cancer of the breast and prostate may belong to the
HNPCC tumor spectrum (Scott et al. 2001; Soravia et al. 2003; Vasen et al. 2001).
Although in general a poor correlation between the type of germline mutation
and clinical phenotype in HNPCC exists (Liu et al. 1996; Peltomaki et al. 2001), in
some cases the predisposing mutation may play an important role in tissue
selection. MSH2 mutation carriers seem to have a higher risk of developing cancer
of the urinary tract, ovaries, stomach, and brain than MLH1 mutation carriers
(Vasen et  al. 2001). It has also been shown that MSH6 mutations are associated
with  families  with  a  higher  incidence  of  EC  (Wijnen et al. 1999). Moreover,
families with different MLH1 mutations  show  different  CRC  to  EC  ratios
according to the predisposing mutation (Table 8).
In addition to the effect of inherited susceptibility, accumulation of mutations
within tumorigenesis may have an effect on organ selection. A MMR defect leads
to accumulation of small insertion/deletion mutations in repeat tracts, which
occur, in addition to non-coding microsatellites, in coding or promoter regulatory
sequences of certain genes. These target genes very likely contribute to the tissue
specificity  according  to  their  expression  pattern  and  functional  importance  in
different cell types. The spectrum of microsatellite mutator pathway target genes
in CRC vs. EC is to some extent overlapping, but for example TGF RII and TCF-4
genes are strongly associated with CRC (Abdel-Rahman et  al. 1999; Duval et  al.
1999; Markowitz et al. 1995), and PTEN with EC (Kuismanen et al. 2002; Zhou et al.
2002).
The proliferation rate of a tissue is also a very important factor in selective organ
susceptibility in HNPCC. Moreover, the rate of change of cell proliferation may
have an important effect (Frank 2004). In the endometrium the monthly cycle of
rapid proliferation followed by rapid apoptosis and regression offers a good
environment for mutation accumulation in MMR deficient cells. Epithelial cells of
the colorectum have also been characterized with variable changes in the
proliferation rate (Lipkin 1973). In the tissues with rapid changes in cell
proliferation rates genes critical for terminating the cell cycle and initiating
apoptosis would be more frequently mutated than in tissues with a steady
proliferation rate. Thus, the endometrium and colorectum have a selection
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advantage for tumor formation, but what determines the differences between EC
and CRC susceptibility?
MMR genes mainly act as tumor suppressor genes, requiring two hits (one in each
allele) before tumor initiation. In HNPCC the first hit is inherited and the second
hit is somatic (Hemminki et al. 1994). We focused on the differential susceptibility
to  HNPCC  associated  CRCs  and  ECs  by  studying  the  role  of  LOH  and MLH1
methylation as second hits required for tumor initiation. Our study agreed nicely
with Knudson’s two hit theory. LOH more frequently affected the wild type allele
than the mutant allele (p=0.003), and it was inversely associated with MLH1
promoter methylation. Moreover, the only tumor showing both LOH at MLH1
locus and MLH1 methylation had lost the mutant allele, suggesting that
methylation affected the wild type allele.
The classical two hit model may, however, not always be fully applicable. For
example, elevated MSI levels have been detected in subjects heterozygous for a
germline mutation, suggesting haploinsufficiency of MMR in cancer initiation
(Alazzouzi et al. 2005). In the case of haploinsufficiency, loss of one allele of a
tumor suppressor is sufficient to accelerate tumorigenesis. Haploinsufficiency can
be partial or complete and it may vary according to tissue type. This might be the
case  in  our  HNPCC series,  in  which LOH and methylation together  served as  a
second hit more frequently in CRCs compared to ECs (p=0.001).
Haploinsufficiency in EC could also explain why the wild type allele LOH
predominated in CRC irrespective of the predisposing mutation, while the wild
type and mutant allele LOH were roughly equally common in ECs from Mut2
and Mut3 carriers.   It  has  also  been shown for  other  genes  that  site  and type of
predisposing germline mutation may affect phenotypic features (Albuquerque et
al. 2002). According to our LOH analyses, a predisposing germline mutation
might  have  some  effect  on  the  dosage  sensitivity.  In  tumors  with  Mut1,  LOH
affected mainly CRC, with only one EC showing LOH (p<0.0001), whereas among
tumors with Mut2 and Mut3 LOH was more common in ECs. We did not address
somatic mutations as second hits, but their role would probably be very modest.
Yuen et al. (2002) and Potocnik et  al. (2001) observed very few MLH1 somatic
mutations in tumors with a MLH1 germline mutation.
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In  summary,  our  findings  of  distinctive  frequencies  of  second  hits  (LOH  and
MLH1 methylation) in CRC vs. EC suggest different dosage requirements of
MLH1 in these two tissues. Moreover, the predisposing germline mutation may
modify  the  dosage  sensitivity.  Taken  together,  the  patterns  of  LOH  and
methylation of tumor suppressor genes are dependent on tissue type and
germline mutation, and may in part explain the differential tumor susceptibility
of different organs in HNPCC.
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CONCLUSIONS AND FUTURE PROSPECTS
This PhD project aimed to molecularly characterize familial colorectal and
endometrial  cancers,  in  both  MMR  deficient  and  proficient  tumors.  The  main
findings may be summarized and concluded as follows:
MMR proficient familial CRC consists of two molecularly distinct groups that
differ from MMR deficient tumors. Group A shows paucity of common molecular
and chromosomal alterations characteristic of colorectal carcinogenesis. Group B
shows molecular features similar to classical microsatellite stable tumors with
gross chromosomal alterations. Our finding of a unique tumor profile in group A
suggests the involvement of novel predisposing genes and pathways in colorectal
cancer cohorts not linked to MMR gene defects. Further studies in larger series of
families are needed to define the nature of predisposing genes that remained
unknown.
Endometrial cancer may be the only manifestation of HNPCC. Among 22 families
with  clustering  of  EC,  two  were  due  to  MMR  gene  germline  mutations.  The
remaining familial site-specific ECs are largely comparable with HNPCC
associated ECs, the main difference between these groups being MMR proficiency
vs. deficiency. The existence of site-specific endometrial carcinoma as a separate
entity remains equivocal until predisposing genes are identified. It is possible that
no single highly penetrant gene for this proposed syndrome exists. It may,
however, be due to a combination of multiple low penetrance genes. Candidates
for familial site-specific EC susceptibility genes may be searched for by genetic
linkage or association based approaches or, alternatively, by tumor-based studies
such as we used here for familial MMR proficient CRCs.
A more refined molecular classification of cancers can be obtained by using
microarrays to perform genome-wide expression profiling, as shown for various
cancers (Boussioutas et al. 2003; Schaner et al. 2003; Sorlie et al. 2001; van 't Veer et
al. 2002).  In  regard  to  CRC,  tumors  with  different  MSI  phenotype  have  been
shown to express different gene subsets by microarray analysis (Mori et al. 2004).
Microarray data has also been used to identify clinically relevant tumor
subgroups (Bertucci et al. 2004). These analyses may provide a useful tool for
defining new genes and pathways in the subset of familial CRCs with stable
microsatellites and chromosomes as well as in the familial site-specific EC. In
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addition, while providing improved classification of CRC and EC, a more
comprehensive molecular understanding of carcinogenesis may one day facilitate
individualized treatment of CRC and EC.
Important determinants of the HNPCC tumor spectrum are, in addition to
different predisposing germline mutations, organ specific target genes and
different instability profiles, loss of heterozygosity at MLH1 locus,  and MLH1
promoter methylation. It will be interesting to see if, besides CRC and EC, the
mechanisms of somatic inactivation also differ between the various other tumors
that are overrepresented in HNPCC.
In conclusion, this study provided more precise molecular classification of
families with clustered CRC and EC that is highly relevant for the proper genetic
counseling of the affected patients and their families. Part of the familial
accumulation of EC is due to a germline mutation in a MMR gene and these
families need to be counseled similar to other HNPCC families. In the case of ECs
the testing for MSI is not as informative predictor of a MMR gene mutation as it is
in  CRCs  where  practically  all  tumors  with  MMR  deficiency  show  unstable
microsatellites. Among familial ECs, tumors with stable microsatellites may as
well harbor a MMR gene germline mutation. The families with accumulated
MMR proficient CRCs also need surveillance since individuals in such families
are at increased risk of developing CRC, although the genetic predisposition still
remained unknown. Our observations on familial CRC and EC are likely to have
broader significance that extends to sporadic CRC and EC as well.
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